US20150045507A1 - Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline - Google Patents
Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline Download PDFInfo
- Publication number
- US20150045507A1 US20150045507A1 US14/385,119 US201314385119A US2015045507A1 US 20150045507 A1 US20150045507 A1 US 20150045507A1 US 201314385119 A US201314385119 A US 201314385119A US 2015045507 A1 US2015045507 A1 US 2015045507A1
- Authority
- US
- United States
- Prior art keywords
- cross
- groups
- pox
- electrophilic
- linking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920006037 cross link polymer Polymers 0.000 title claims abstract description 83
- 229940127554 medical product Drugs 0.000 title claims abstract description 39
- 229920000765 poly(2-oxazolines) Polymers 0.000 title claims abstract description 29
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 107
- 230000000269 nucleophilic effect Effects 0.000 claims abstract description 72
- 239000007943 implant Substances 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims abstract description 12
- 239000012948 isocyanate Substances 0.000 claims abstract description 9
- -1 p-nitrothiophenyl esters Chemical class 0.000 claims description 106
- 229920000642 polymer Polymers 0.000 claims description 89
- 230000001070 adhesive effect Effects 0.000 claims description 30
- 239000012530 fluid Substances 0.000 claims description 27
- 239000000853 adhesive Substances 0.000 claims description 24
- 239000000178 monomer Substances 0.000 claims description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 229920002307 Dextran Polymers 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 239000000565 sealant Substances 0.000 claims description 16
- 230000000025 haemostatic effect Effects 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 150000001299 aldehydes Chemical class 0.000 claims description 12
- 229940030225 antihemorrhagics Drugs 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical class OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 claims description 10
- IURPJDIWBPNRPJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) carbamate Chemical class NC(=O)ON1C(=O)CCC1=O IURPJDIWBPNRPJ-UHFFFAOYSA-N 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 9
- PPWKULKZXZDYRP-UHFFFAOYSA-N 1-carboxyoxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical class OC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O PPWKULKZXZDYRP-UHFFFAOYSA-N 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 150000002513 isocyanates Chemical group 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 7
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims description 7
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical class C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 150000002463 imidates Chemical class 0.000 claims description 6
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 claims description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 5
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 5
- 150000002118 epoxides Chemical class 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 5
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims description 5
- 150000007970 thio esters Chemical class 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- 229920001218 Pullulan Polymers 0.000 claims description 4
- 239000004373 Pullulan Substances 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229960002900 methylcellulose Drugs 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000019423 pullulan Nutrition 0.000 claims description 4
- 239000003356 suture material Substances 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229940050528 albumin Drugs 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 229940051593 dermatan sulfate Drugs 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 2
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 claims 2
- 238000007789 sealing Methods 0.000 abstract description 7
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 44
- 239000000203 mixture Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 29
- 238000001356 surgical procedure Methods 0.000 description 29
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 26
- 239000010408 film Substances 0.000 description 25
- 238000004132 cross linking Methods 0.000 description 23
- 230000008439 repair process Effects 0.000 description 21
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 19
- 229940086542 triethylamine Drugs 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 239000003106 tissue adhesive Substances 0.000 description 16
- 239000004971 Cross linker Substances 0.000 description 14
- 239000000017 hydrogel Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- 229920001002 functional polymer Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 150000004702 methyl esters Chemical class 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- GUXJXWKCUUWCLX-UHFFFAOYSA-N 2-methyl-2-oxazoline Chemical group CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 230000003872 anastomosis Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 150000003573 thiols Chemical group 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920001519 homopolymer Polymers 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- NIRYAMUQLIEZLP-UHFFFAOYSA-N methyl 3-(4,5-dihydro-1,3-oxazol-2-yl)propanoate Chemical compound COC(=O)CCC1=NCCO1 NIRYAMUQLIEZLP-UHFFFAOYSA-N 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 229940075469 tissue adhesives Drugs 0.000 description 7
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 229920001222 biopolymer Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 6
- 230000009477 glass transition Effects 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 5
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 5
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- QMKYBPDZANOJGF-UHFFFAOYSA-N benzene-1,3,5-tricarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC(C(O)=O)=C1 QMKYBPDZANOJGF-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000010538 cationic polymerization reaction Methods 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 229960003151 mercaptamine Drugs 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000003871 sulfonates Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- GXCJLVVUIVSLOQ-UHFFFAOYSA-N 2-propyl-4,5-dihydro-1,3-oxazole Chemical compound CCCC1=NCCO1 GXCJLVVUIVSLOQ-UHFFFAOYSA-N 0.000 description 3
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920000855 Fucoidan Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000012861 aquazol Substances 0.000 description 3
- 229920006189 aquazol 50 Polymers 0.000 description 3
- 239000012863 aquazol 50 Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000003335 secondary amines Chemical group 0.000 description 3
- 238000000807 solvent casting Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 2
- LCPNYLRZLNERIG-ZETCQYMHSA-N (2S)-6-amino-2-[2-(oxomethylidene)hydrazinyl]hexanoyl isocyanate Chemical compound NCCCC[C@H](NN=C=O)C(=O)N=C=O LCPNYLRZLNERIG-ZETCQYMHSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- XWGXLRRTBBCVMC-UHFFFAOYSA-N 2-methylbutanedioyl dichloride Chemical compound ClC(=O)C(C)CC(Cl)=O XWGXLRRTBBCVMC-UHFFFAOYSA-N 0.000 description 2
- 206010060954 Abdominal Hernia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 229920000018 Callose Polymers 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 229920000887 Chrysolaminarin Polymers 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NIBVDXPSJBYJFT-VBBCUDLLSA-N Planteose Natural products O(C[C@@H]1[C@H](O)[C@@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1 NIBVDXPSJBYJFT-VBBCUDLLSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 229920000617 arabinoxylan Polymers 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical class C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- IGWTZHMYJZZIGC-VIFPVBQESA-N ethyl (2s)-2,6-diisocyanatohexanoate Chemical compound CCOC(=O)[C@@H](N=C=O)CCCCN=C=O IGWTZHMYJZZIGC-VIFPVBQESA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000009474 hot melt extrusion Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- YDSWCNNOKPMOTP-UHFFFAOYSA-N mellitic acid Chemical compound OC(=O)C1=C(C(O)=O)C(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1C(O)=O YDSWCNNOKPMOTP-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- NIBVDXPSJBYJFT-ZQSKZDJDSA-N planteose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 NIBVDXPSJBYJFT-ZQSKZDJDSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000002278 reconstructive surgery Methods 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 150000003334 secondary amides Chemical class 0.000 description 2
- 239000012890 simulated body fluid Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 2
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical class [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WGJCBBASTRWVJL-UHFFFAOYSA-N 1,3-thiazolidine-2-thione Chemical compound SC1=NCCS1 WGJCBBASTRWVJL-UHFFFAOYSA-N 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- GODZNYBQGNSJJN-UHFFFAOYSA-N 1-aminoethane-1,2-diol Chemical compound NC(O)CO GODZNYBQGNSJJN-UHFFFAOYSA-N 0.000 description 1
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical compound CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JNAQYWWCTUEVKR-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)ethanamine Chemical compound NCCC1OCCO1 JNAQYWWCTUEVKR-UHFFFAOYSA-N 0.000 description 1
- YCXAJRQGOJOKOX-UHFFFAOYSA-N 2-(4,5-dihydro-1,3-oxazol-2-yl)ethanamine Chemical group NCCC1=NCCO1 YCXAJRQGOJOKOX-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JEPCLNGRAIMPQV-UHFFFAOYSA-N 2-aminobenzene-1,3-diol Chemical compound NC1=C(O)C=CC=C1O JEPCLNGRAIMPQV-UHFFFAOYSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- NOYDZPBTPYIKTL-UHFFFAOYSA-N 2-but-1-enyl-4,5-dihydro-1,3-oxazole Chemical compound CCC=CC1=NCCO1 NOYDZPBTPYIKTL-UHFFFAOYSA-N 0.000 description 1
- QQHITEBEBQNARV-UHFFFAOYSA-N 3-[[2-carboxy-2-(2,5-dioxopyrrolidin-1-yl)-2-sulfoethyl]disulfanyl]-2-(2,5-dioxopyrrolidin-1-yl)-2-sulfopropanoic acid Chemical compound O=C1CCC(=O)N1C(S(O)(=O)=O)(C(=O)O)CSSCC(S(O)(=O)=O)(C(O)=O)N1C(=O)CCC1=O QQHITEBEBQNARV-UHFFFAOYSA-N 0.000 description 1
- FLROJJGKUKLCAE-UHFFFAOYSA-N 3-amino-2-methylphenol Chemical compound CC1=C(N)C=CC=C1O FLROJJGKUKLCAE-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- NWAGXLBTAPTCPR-UHFFFAOYSA-N 5-(2,5-dioxopyrrolidin-1-yl)oxy-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)ON1C(=O)CCC1=O NWAGXLBTAPTCPR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 208000032750 Device leakage Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 208000012258 Diverticular disease Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010052211 Oesophageal rupture Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 206010073024 Preterm premature rupture of membranes Diseases 0.000 description 1
- 241000083513 Punctum Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000002152 Splenic rupture Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046451 Urethral fistula Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010065813 Vaginal fistula Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical class CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000012656 cationic ring opening polymerization Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000004711 cerebrospinal fluid leak Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- IFDVQVHZEKPUSC-UHFFFAOYSA-N cyclohex-3-ene-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCC=CC1C(O)=O IFDVQVHZEKPUSC-UHFFFAOYSA-N 0.000 description 1
- QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 1
- 229940075482 d & c green 5 Drugs 0.000 description 1
- 229940096890 d&c violet no. 2 Drugs 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000005678 ethenylene group Chemical class [H]C([*:1])=C([H])[*:2] 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010879 hemorrhoidectomy Methods 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002691 malonic acids Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KQTSOJHOCCWAEH-UHFFFAOYSA-N n'-(2,5-dioxopyrrolidin-1-yl)butanediamide Chemical compound NC(=O)CCC(=O)NN1C(=O)CCC1=O KQTSOJHOCCWAEH-UHFFFAOYSA-N 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000548 poly(silane) polymer Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000412 polyarylene Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002480 polybenzimidazole Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- TVRGPOFMYCMNRB-UHFFFAOYSA-N quinizarine green ss Chemical compound C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1 TVRGPOFMYCMNRB-UHFFFAOYSA-N 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- HHSGWIABCIVPJT-UHFFFAOYSA-M sodium;1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 HHSGWIABCIVPJT-UHFFFAOYSA-M 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical group [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- LJFWQNJLLOFIJK-UHFFFAOYSA-N solvent violet 13 Chemical compound C1=CC(C)=CC=C1NC1=CC=C(O)C2=C1C(=O)C1=CC=CC=C1C2=O LJFWQNJLLOFIJK-UHFFFAOYSA-N 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UFDHBDMSHIXOKF-UHFFFAOYSA-N tetrahydrophthalic acid Natural products OC(=O)C1=C(C(O)=O)CCCC1 UFDHBDMSHIXOKF-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013162 therapeutic embolization Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2379/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2361/00 - C08J2377/00
- C08J2379/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2312/00—Crosslinking
Definitions
- the invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting nucleophilically activated polyoxazoline (NU-POX) with an electrophilically activated cross-linking agent.
- NU-POX nucleophilically activated polyoxazoline
- kits for producing a biocompatible, cross-linked polymer from NU-POX with an electrophilically activated cross-linking agent are provided.
- the invention further provides a medical product comprising at least 1% by weight of dry matter of said cross-linked polymer.
- medical products are medical implants including bone implants, soft tissue implants, adhesive implants, coatings on implants, sutures, adhesive tissue sealants and adhesive tissue tapes.
- Tissue adhesives have many potential medical applications, including wound closure, supplementing or replacing sutures or staples in surgical procedures, adhesion of synthetic onlays or inlays to the cornea, drug delivery devices, and as anti-adhesion barriers to prevent post-surgical adhesions.
- tissue adhesives include fibrin sealants, cyanoacrylate based sealants, and other synthetic sealants and polymerizable macromers. Some of these conventional sealants are only suitable for a specific range of adhesive applications. For example, cyanoacrylate-based adhesives have been used for topical wound closure, but the release of toxic degradation products limits their use for internal applications. Fibrin-based adhesives are expensive, often need refrigerated storage, are slow curing, have limited mechanical strength, and pose a risk of viral infection.
- ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, abdominal hernias, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants
- neurosurgery applications such as sealing the dura; plugging to seal a fistula or the punctum, slow degrading tissue adhesives are needed.
- hydrogel tissue adhesives have improved adhesive properties and are non-toxic.
- Most of these hydrogel tissue adhesives like DuraSeal®, are chemically based on a process called PEGylation used in polymer-modified therapeutics with reactive polyethylene glycol (PEG) precursors like, for instance, PEG-succinimidyl glutarate.
- PEG polyethylene glycol
- These hydrogel tissue adhesives typically swell or dissolve away too quickly, or lack sufficient cohesion (interconnecting mechanical strength), thereby decreasing their effectiveness as surgical adhesives.
- dual syringe spray technology may be needed, which demands extensive sample preparation from freeze dried starting materials.
- the properties of such PEG-based materials cannot be easily controlled and the number of NHS-groups is limited to the number of chain ends; possibly comprising multiple NHS groups per chain end resulting in a high NHS group density rather than regularly distributed groups.
- WO 2002/062276 describes a hydrogel tissue sealant comprising a star-shaped PEG-succinimidyl glutarate precursor, also known as star-PEG-NHS or star-PEG-NS or star-SG-PEG or star-PEG-SG, that reacts with a trilysine precursor.
- the star-SG-PEG precursor may be reconstituted in pH 4 phosphate, while the trilysine precursor may be reconstituted in pH 8 borate buffer.
- covalent amide bonds between amines of the trilysine precursor and NHS-activated terminal carboxylate groups of the star-SG-PEG precursor are formed.
- WO 2010/059280 describes an anhydrous fibrous sheet comprising a first component of fibrous polymer, said polymer containing electrophilic groups or nucleophilic groups, and a second component capable of crosslinking the first component when said sheet is exposed to an aqueous medium to form a crosslinked hydrogel that is adhesive to biological tissue.
- the examples of the international patent application describe the preparation of fibrous sheets comprising dextran aldehyde and multi-arm polyethylene glycol amine.
- WO 00/33764 describes a method for preparing a biocompatible crosslinked polymer, comprising:
- WO 2005/109248 describes cross-linked polymeric compositions of hydrolyzed poly(2-alkyl-2-oxazoline) and the use of these cross-linked polymeric compositions in color ink-jet ink.
- WO 2009/043027 describes multiarmed, monofunctional derivatives of polyoxazolines, as well as conjugates of such polyoxaline derivatives with drugs.
- a polymer having excellent implant and/or sealing characteristics can be obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) and at least two nucleophilic groups with a cross-linking agent that comprises at least two electrophilic groups, said cross-linking agent not being an electrophilically activated polyoxazoline.
- NU-POX nucleophilically activated polyoxazoline
- cross-linking agent that comprises at least two electrophilic groups
- the invention provides a biocompatible medical product comprising a covalently cross-linked, polymer that is obtained by reacting a NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m ⁇ 2, n ⁇ 2 and m+n ⁇ 5, and wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate.
- biocompatible medical products include implants, tissue sealants, adhesive tissue tape, suture materials, polymer coated stents and haemostatic materials.
- the cross-linked polymer of the present invention provides a number of beneficial properties:
- Another aspect of the invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m ⁇ 2, n ⁇ 2 and m+n ⁇ 5; wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate; and wherein the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably at least 5%.
- kits for producing a biocompatible, cross-linked polymer comprising the NU-POX and the electrophilically activated cross-linking agent described herein before.
- This kit may suitably be used to deliver bone substitute materials, anti-adhesive implants (films), adhesive implants (for instance a tissue sealant for closing arterial puncture sites, or for embolization or to treat urinary incontinence).
- the rate at which cross-linking occurs when the NU-POX and the electrophilically activated cross-linking agent are brought together can be controlled effectively by including non-inert fluids, such as water (various pH), alcohols and/or polyols.
- non-inert fluids such as water (various pH), alcohols and/or polyols.
- one aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) with an electrophilically activated cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups, and said electrophilically activated cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds, wherein m ⁇ 2, n ⁇ 2 and m+n ⁇ 5, wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate.
- NU-POX nucleophilically activated polyoxazoline
- polyoxazoline refers to a poly(N-acylalkylenimine) or a poly(aroylalkylenimine) and is further referred to as POX.
- polyoxazoline as used herein also encompasses POX copolymers.
- electrophilically activated cross-linking agent refers to a polyoxazoline containing at least 2 electrophilic groups, notably electrophilic groups selected from electrophilic groups contained in the EL-POX are selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato, isocyano, epoxides, activated hydroxyl groups, olefins, glycidyl ethers, carboxyl, succinimidyl ester, succinimidyl carbonate, succinimidyl carbamates, sulfosuccinimidyl ester, sulfosuccinimidyl carbonate,
- pendant nucleophilic group refers to a nucleophilic group that is comprised in a side chain, e.g. an alkyl or aryl side chain, of the POX polymer, as opposed to a nucleophilic group that is located at a terminus of the POX polymer chain. It should be understood that a particular side chain of the POX polymer may suitably contain more than one nucleophilic group, in which case each nucleophilic group within that particular side chain counts as a pendant nucleophilic group.
- amine groups refers to primary or secondary amine groups.
- the NU-POX or the cross-linked polymer of the present invention is characterized on the basis of the presence of a certain number of particular groups or bonds per 100 monomers it should be understood that this does not imply that the polymer contains at least 100 monomers.
- a NU-POX comprising 80 monomers and 8 pendant groups contains 10 pendant groups per 100 monomers.
- this polymer contains, for instance, at least x pendant groups per 100 monomers, this criterion is met if this particular polymer contains on average at least 0.8x pendant groups.
- the NU-POX of the present invention is a nucleophilically activated version of a polyoxazoline polymer whose repeating units are represented by the following formula (I):
- R 2 and each of R 1 independently being selected from H, optionally substituted C 1-22 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted aryl; and m being 2 or 3.
- the invention also encompasses the use of polyoxazolines copolymers that comprise two or more different repeating units that are represented by formula (I).
- R 1 and R 2 in formula (I) are selected from H and C 1-22 alkyl, even more preferably from H and C 1-4 alkyl.
- R 1 most preferably is H.
- the integer m in formula (I) is preferably equal to 2.
- the polyoxazoline employed in accordance with the present invention is a polymer, more preferably a homopolymer, of 2-alkyl-2-oxazoline, said 2-alkyl-2-oxazoline being selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-propyl-2-oxazoline, and combinations thereof. Even more preferably, the 2-alkyl-oxazoline is selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline and combinations thereof. Most preferably, the 2-alkyl-2-oxazoline is 2-methyl-oxazoline.
- the NU-POX employed in accordance with the present invention advantageously contains at least 40, even more preferably at least 50 and most preferably at least 100 (monomeric) oxazoline units.
- At least one of the two reactants employed in the cross-linked polymer of the present invention is a polymer having a degree of polymerization of at least 20, more preferably at least 30, even more preferably of least 50 and most preferably of at least 100.
- the NU-POX contains at least 20, even more preferably at least 30, yet more preferably at least 50 and most preferably at least 100 (monomeric) oxazoline units
- the NU-POX employed in accordance with the present invention contains pendant nucleophilic groups, terminal nucleophilic groups, or a combination thereof.
- at least one of the m nucleophilic groups in the NU-POX being part of the biocompatible cross-linked polymer according to any of the foregoing is a pendant nucleophilic group.
- said NU-POX contains 3 to 50 pendant nucleophilic groups per 100 monomers in the cross-linked polymer, more preferably 5 to 20 pendant electrophilic groups per 100 monomers in the cross-linked polymer.
- the cross-linked polymer has tissue-adhesive properties.
- tissue adhesive e.g. amine or thiol
- the unreacted electrophilic groups contained in the cross-linked polymer are capable of reacting with nucleophilic (e.g. amine or thiol) groups that are naturally present in tissue to form covalent bonds.
- nucleophilic e.g. amine or thiol
- the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably by at least 5%, even more preferably by at least 10% and most preferably by at least 20%.
- the tissue adhesive properties of the cross-linked polymer can be controlled very effectively by manipulating the number of non-reacted electrophilic groups in the cross-linked polymer. Generally speaking, the higher the number of non-reacted electrophilic groups, the stronger the adhesion.
- the cross-linked polymer comprises, per 100 NU-POX monomers, at least 2, more preferably at least 5 and most preferably at least 10 electrophilic groups of the electrophilic cross-linking agent that have not reacted with a nucleophilic group of the NU-POX.
- the m nucleophilic groups on NU-POX are selected from amine groups, thiol groups, phosphine groups and combination thereof. Even more preferably, the nucleophilic groups are selected from amine groups, thiol groups and combinations thereof.
- the nucleophilic groups present in the NU-POX are amine groups.
- An amine functionalized NU-POX can suitably be derived from a homopolymer or copolymer of cysteamine modified 2-alkenyl-2-oxazoline or 2-t-BOC-aminoalkyl-2-oxazoline and 2-alkyl-2-oxazoline.
- the cysteamine modified 2-alkenyl-2-oxazoline comprised in the copolymer is preferably selected from 2-butenyl-2-oxazoline, and combinations thereof.
- the 2-alkyl-2-oxazoline is preferably selected from 2-ethyl-2-oxazoline, 2-methyl-2-oxazoline, 2-propyl-2-oxazoline and combinations thereof.
- the amine moieties can also be introduced by partial hydrolysis of POX followed by alkylation or amidation of the resulting secondary amine groups in the polymer chain.
- the m nucleophilic groups present in the NU-POX are thiol (sulfohydryl) groups.
- the NU-POX is a poly(2-alkyl-2-oxazoline) with thiol terminal groups that have been introduced by endcapping the polymerization with a multifunctional initiator with potassium xanthogenate followed by aminolysis to get the free thiol groups.
- the thiol moieties are introduced into the side chains of the NU-POX by copolymerization of a protected thiol containing monomer or by modification of acid, amine or alkenyl side chains or by modification of the backbone secondary amines resulting from partial hydrolysis.
- the 2-alkyl-2-oxazoline is preferably selected from 2-ethyl-2-oxazoline, 2-methyl-2-oxazoline, 2-propyl-2-oxazoline and combinations thereof.
- the NU-POX contains oxazoline units containing a nucleophilic group and oxazoline units containing no nucleophilic group in a molar ratio that lies within the range of 1:50 to 1:1, more preferably in a molar ratio that lies within the range of 3:100 to 1:2.
- the NU-POX employed in accordance with the present invention typically has a molecular weight in the range of 1,000 to 100,000 g/mol, more preferably of 5,000 to 50,000 and most preferably of 10,000 to 30,000 g/mol.
- NU-POX employed in accordance with the present invention can be a homopolymer or a copolymer. Most preferably, NU-POX is a copolymer.
- the electrophilically activated cross-linking agent employed in accordance with the present invention contains a backbone that carries or is substituted with n ⁇ 2 electrophilic groups.
- the backbone preferably is chosen from the group consisting of polymers, diacids, triacids or higher acids.
- the backbone of the electrophilically activated cross-linking agent is not a polyoxazoline.
- the backbone of the electrophilically activated cross-linking agent is selected from the group of polymers consisting of polyesters, polyolefins, polystyrenes, polycarbonates, polyamides, polyacetates, poly(alkylene oxalates), polyanhydrides, poly iminocarbonates, polyoxaesters, polyorthoesters, polyphosphazenes, polyphosphoesters, polyethers, polyetheresters, polyacrylamides, polyimides, polyphenylenes, polysilanes, polysiloxanes, polybenzimidazoles, polybenzothiazoles, polysulfides, polyesteramides, polyetheramides, polyamines, polyetheramines, polyarylene vinylenes, polyether ketones, polyurethanes, polysulfones, polyacrylates, polymethacrylates, polysaccharides, glycosaminoglycans, polypeptides, and combinations thereof.
- these polymers have
- the backbone of the electrophilically activated cross-linking agent is selected from the group of polymers consisting of agar, starch, pullulan, inulin, levan, silk, fibronectin, pectin, cellulose (e.g.
- the backbone of the electrophilically activated cross-linking agent may suitably be selected from the group of polysaccharides consisting of dextran (e.g.
- carboxymethyldextran carboxymethyldextran
- starch agar
- cellulose pullulan inulin
- levan agar
- cellulose pullulan inulin
- levan agar
- hyaluronic acid agar
- the latter polysaccharides are employed in a (partially) oxidized form.
- the electrophilic cross-linking agent is selected from the group of polymers consisting of dextran, collagen, gelatin (gelfoam), alginic acid and polyethylene glycol.
- the electrophilic cross-linking agent employed in the biocompatible cross-linked polymer is a low molecular weight electrophilic cross-linker having a molecular weight of 80-1000 g/mol, preferably of 100-500 g/mol.
- low molecular cross-linking agents include multialdehydes, multimaleimides, multi-activated esters and combinations thereof (here the term ‘multi’ means at least two).
- the low-molecular cross-linker has a backbone consisting of an acid selected from the group consisting of diacids, triacids and higher acids modified with N-hydroxysuccinimide (NHS) or sulfo-NHS.
- the acid-based cross-linking agent is selected from diacids, triacids and combinations thereof.
- diacids and triacids that may be employed are diglycolic acid, oxalic acids, malonic acids, malic acid, tartaric acid, maleic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, phthalic acid, tetrahydrophthalic acid, hexahydrophthalic acid, trimesic acid, mellitic acid, isophthalic acid, terephthalic acid, citric acid, isocitric acid, aconitic acid, tricarballylic acid and trimesic acid.
- the acid that forms the backbone of the electrophilic cross-linking agent is selected from triacids, most preferably citric acid.
- the acid-based cross-linking agent is selected from the group of amino carboxylic acids.
- amino carboxylic acids that may be employed are: Fura-2, iminodiacetic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylene triamine pentaacetic acid, ethylene glycol tetraacetic acid, (1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and oligopeptides based on glutamic acid and/or aspartic acid.
- the electrophilic cross-linking agent is a polymer having a molecular weight in excess of 1000 g/mol, more preferably of 2000-10000 g/mol and most preferably of 5000-50000 g/mol.
- the use of polymeric electrophilic cross-linking agents offers the advantage that the excess electrophilic groups are further away from the crosslinking points thereby increasing their mobility and ability to couple to tissue.
- the electrophilic groups contained in the cross-linking agent preferably are highly reactive towards the nucleophilic groups contained in the NU-POX, preferably at ambient and/or physiological conditions.
- the electrophilic groups present in the cross-linking agent are preferably selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato (isothiocyanato), epoxides, activated hydroxyl groups, glycidyl ethers, carboxyl, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates, maleimides, imido esters, orthopyridyl disulfide, dihydroxy-phenyl derivatives, vinyl, acrylate, acrylamide, iodoacetamide
- Examples of sulfonate esters that can be used as electrophilic groups include mesylate, tosylate, nosylate, triflate and combinations thereof.
- Examples of activated hydroxyl groups include hydroxyl groups that have been activated with an activating agent selected from p-nitrophenyl chlorocarbonates, carbonyldiimidazoles (e.g. 1,1-carbonyl diimidazole) and sulfonyl chloride.
- succinimidyl derivatives examples include succinimidyl glutarate, succinimidyl propionate, succinimidyl succinamide, succinimidyl carbonate, disuccinimidyl suberate, bis(sulfosuccinimidyl) suberate, dithiobis(succinimidylpropionate), bis(2-succinimidooxycarbonyloxy) ethyl sulfone and 3,3′-dithiobis(sulfosuccinimidyl-propionate).
- sulfosuccinimidyl derivatives examples include sulfosuccinimidyl(4-iodoacetyl)aminobenzoate, bis(sulfosuccinimidyl) suberate, sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, dithiobis-sulfosuccinimidyl propionate, disulfo-succinimidyl tartarate; bis[2-(sulfo-succinimidyloxycarbonyloxyethyl sulfone)], ethylene glycol bis(sulfosuccinimiclylsuccinate), dithiobis-(succinimidyl propionate).
- dihydroxyphenyl derivatives examples include dihydroxyphenylalanine, 3,4-dihydroxyphenylalanine (DOPA), dopamine, 3,4-dihydroxyhydroccinamic acid (DOHA), norepinephrine, epinephrine and catechol.
- DOPA 3,4-dihydroxyphenylalanine
- DOHA 3,4-dihydroxyhydroccinamic acid
- norepinephrine norepinephrine
- epinephrine epinephrine
- catechol catechol
- the m ⁇ 2 nucleophilic groups of the NU-POX are amine groups, preferably primary amine groups
- the n ⁇ 2 electrophilic groups comprised in the electrophilically activated cross-linking agent are selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato, epoxides, activated hydroxyl groups, glycidyl ethers, carboxyl, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates, imido esters, dihydroxy-phenyl derivatives
- the electrophilic groups contained in the cross-linking agent are selected from aldehydes, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, imido esters, dihydroxyphenyl derivatives and combinations thereof. Most preferably, the electrophilic groups are selected from the group of N-hydroxysuccinimide esters, aldehydes, dihydroxyphenyl derivatives and combinations thereof.
- the m ⁇ 2 nucleophilic groups of the NU-POX are thiol groups and the n ⁇ 2 electrophilic groups contained in the electrophilically activated cross-linking agent are selected from halo acetals, orthopyridyl disulfide, maleimides, vinyl sulfone, dihydroxyphenyl derivatives, vinyl, acrylate, acrylamide, iodoacetamide, succinimidyl esters, succinimidyl carbonate, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates and combinations thereof.
- the electrophilic groups are selected from succinimidyl esters, halo acetals, maleimides, or dihydroxyphenyl derivatives and combinations thereof.
- the n ⁇ 2 electrophilic groups are selected from maleimides or dihydroxyphenyl derivatives and combinations thereof.
- the m ⁇ 2 nucleophilic groups comprised in the NU-POX component of the cross-linked polymer are capable of reacting with the n ⁇ 2 electrophilic groups of the cross-linking agent under ambient and/or physiological conditions to form covalent bonds.
- Non-reacted electrophilic groups in the cross-linked polymer of the present invention impart tissue adhesive properties to the polymer as they can react with nucleophilic groups (e.g amino groups and thiol groups) that are naturally present in tissue.
- nucleophilic groups e.g amino groups and thiol groups
- the non-reacted electrophilic groups can react with nucleophilic groups of the tissue, thereby creating strong adhesion between the polymer and the tissue.
- the ability to form cross-links at ambient temperature is especially advantageous if the cross-linking should occur in situ during e.g. surgery.
- the cross-linking reaction between the NU-POX and the cross-linking agent is completed within 30 minutes, preferably within 10 minutes, more preferably within 5 minutes, most preferably within 2 minutes.
- the ability of the (dry) cross-linked polymer to swell when contacted with water, next to its overall hydrophobicity, depends strongly on the level of cross-linking. The more cross-linking, the lower the swelling index.
- the polymer contains, per 100 monomers, not more than 50, more preferably not more than 20 and most preferably not more than 10 of covalent bonds that have been formed by the reaction between the nucleophilic groups of the NU-POX and the electrophilic groups of the cross-linking agent. Typically, this number of covalent bonds is at least 2 per 100 monomers.
- NU-POX comprising pendant nucleophilic groups
- NU-POX comprising pendant nucleophilic groups
- POX-derivatives containing activated groups in the side chain can be prepared directly from the 2-oxazoline monomer containing the required (protected) group, or by a polymer analogous reaction of polymer precursors. Synthesis of a functional group at the POX terminus is, for instance, described by Anna Mero et. al. ( Synthesis and characterization of poly (2- ethyl 2- oxazoline )- conjugates with proteins and drugs: Suitable alternatives to PEG - conjugates? , Journal of Controlled Release 125 (2008) 87-95).
- NU-POX containing ethyl and amino (—NH 2 ) groups in the alkyl side chain can be synthesized by reaction of poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer with cysteamine, by copolymerization of a protected amine monomer with 2-ethyl-2-oxazoline or by partial hydrolysis of POX followed by post-modification.
- NU-POX containing ethyl and thiol (—SH) groups in the alkyl side chain can be prepared in a similar fashion by reaction of poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer with an excess of ethanedisulfide, by copolymerization of 2-ethyl-2-oxazoline with a monomer bearing a protected thiol group or by partial hydrolysis of POX followed by post-modification.
- biodegradability can range from essentially non-degradable to easily degradable. Biodegradability can be improved by incorporation of an ester link that is more readily hydrolyzed than the secondary amides resulting from reactions between the NHS-ester and amines.
- the ester groups are directly hydrolyzed in aqueous environment by reaction with water while the secondary amides are mainly hydrolyzed by enzymatic degradation that will be very slow in the cross-linked network, at neutral pH.
- Cationic polymerization enables the synthesis of copolymers with a predefined number of activated groups. Furthermore, cationic 2-alkyl-2-oxazoline polymerization can be used to incorporate a large number of active groups as these active groups are coupled to the numerous alkyl side chains of the POX. This again makes it possible to produce highly cross-linked polymers with excellent cohesive properties as well as outstanding adhesive properties in case the cross-linked polymer has a high density of unreacted electrophilic groups.
- cationic polymerization allows the incorporation of various functional groups in the side-chain and/o terminus, thereby enhancing the versatility of the POX polymer system.
- a copolymer containing a predefined number of activated groups per copolymer can be carried out as follows: a copolymer is synthesized by cationic polymerization of ETOX and BUTOX, as described previously, to yield a poly[2-(ethyl/3-butenyl)-2-oxazoline copolymer. Upon functionalization of the activated side chains with e.g. cysteamine, primary amine groups are introduced. In case the initial ETOX/BUTOX molar ratio is 90/10, the percentage of reactive groups per poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer, will be 10%.
- Increasing the BUTOX in the initial 90/10 ETOX/BUTOX mixture will eventually result in a higher percentage of amino groups, i.e. more than 10%.
- the exact number of incorporated amino groups can be controlled by the ratio of monomer to initiator that determines the length of the polymer. For example, using an ETOX/BUTOX ratio of 90/10 and a monomer to initiator ratio of 100:1 yields polymers with 100 repeat units comprising 10 amino groups. When the monomer to initiator ratio is changed to 200:1 the resulting copolymer will have 20 amino groups with the same ETOX/BUTOX ratio.
- the cross-linked polymer of the present invention may be biodegradable or non-biodegradable.
- the polymer is biodegradable.
- the medical product of the present invention preferably comprises at least 25% and most preferably 50-100% by weight of dry matter of a cross-linked polymer as defined herein before.
- Preferred examples of such medical products include implants, tissue sealants, adhesive tissue tape, adhesive tissue film (sheet), suture material, polymer coated stents and haemostatic (porous) materials.
- the medical product may suitable contain other pharmaceutically acceptable components besides the cross-linked polymer.
- a polymer that is not part of the cross-linked polymer examples include aphipathic polymers (such as collagen, gelatin and fibrin), neutral biopolymers (such as dextran and agarose) or ionic polymers.
- the ionic polymers may be cationic (such as chitin or chitosan) or anionic.
- a suitable anionic polymer is, for example, a synthetic polymer, biopolymer or modified biopolymer comprising carboxy, sulfo, sulfato, phosphono or phosphato groups or a mixture thereof, or a salt thereof, for example a biomedical acceptable salt.
- Examples of synthetic anionic polymers are: a linear polyacrylic acid (PAA), a branched polyacrylic acid, for example a Carbophil® or Carbopol® type from Goodrich Corp., a poly-methacrylic acid (PMA), a polyacrylic acid or polymethacrylic acid copolymer, for example a copolymer of acrylic or methacrylic acid and a further vinylmonomer, for example acrylamide, N.N-dimethyl acrylamide or N-vinylpyrrolidone, a maleic or fumaric acid copolymer, a poly(styrenesulfonic acid) (PSS), a polyamido acid, for example a carboxy-terminated polymer of a diamine and a di- or polycarboxylic acid, for example carboxy-terminated StarburstTM PAMAM dendrimers (Aldrich), a poly(2-acrylamido-2-methylpropanesulfonic acid) (poly-(
- anionic biopolymers or modified biopolymers are: hyaluronic acid (HA), modified HA (esterified HA or amine modified HA), glycosamino-glycanes such as heparin or chondroitin sulfate, fucoidan, poly-aspartic acid, poly-glutamic acid, carboxymethyl cellulose, carboxymethyl dextranes, alginates, pectins, gellan, carboxyalkyl chitins, carboxymethyl chitosans, sulfated polysaccharides.
- Preferred anionic biopolymers are alginic acid, hyaluronic acid.
- the cross-linked polymer can be formed into shape by solvent casting, hot melt extrusion or electrospinning. It is also feasible to shape the cross-linked polymer by means of compression between two heated plates as described, for instance, in WO 2007/099370.
- the cross-links between the nucleophilic groups of the NU-POX and the electrophilic groups of the crosslinking agent provide cohesion and the excess of electrophilic groups enables the cross-linked polymer to form links to tissue.
- the present invention enables the preparation of medical products that combine cohesiveness with adhesiveness.
- a very important property of POX films is that upon thorough drying to remove water they protect the interior from hydrolysis. Thus, excess (non-reacted) electrophilic groups in the crosslinked polymer will retain their activity upon storage.
- an electrophilic-nucleophilic reaction will occur between these electrophilic groups and nucleophilic reactants, notably amino or thiol groups present in tissue, thereby forming a cross linked external network (adhesion) via covalent bonding.
- the medical product advantageously is a dehydrated product containing less than 10%, even more preferably less than 5% and most preferably less than 1% water by weight of the cross-linked polymer.
- the medical product preferably contains not more than a limited amount of organic solvent.
- the product preferably contains less than 5%, more preferably less than 0.5% organic solvent by weight of the cross-linked polymer.
- NU-POX and cross-linking agent can be mixed in any ratio needed by solvent casting or hot melt extrusion. This approach enables very precise fine tuning of the properties needed for an adhesive tissue tape or film.
- the amount of nucleophilic groups in the NU-POX is low and the number of electrophilic groups provided by the cross-linking agent is relatively high, cohesion of the resulting cross-linked polymer will be low and adhesion to tissue will be high.
- it is also feasible to produce an adhesive tissue tape or film with high cohesion and high adhesion by combining a NU-POX having a high density of nucleophilic groups with an excess amount of electrophilic cross-linking agent.
- a particularly advantageous embodiment of the present medical product is an adhesive tissue tape or an adhesive tissue film.
- the present invention enables the preparation of a tape or film with excellent tissue-adhesive properties due to the presence of non-reacted electrophilic groups that are capable of reacting with nucleophilic groups naturally present in tissue.
- the cross-linked polymer of the present invention due to its amorphous properties and tunable glass transition temperature, enables the preparation of cohesive, flexible and resilient tapes and films as well as tough and harder materials tailor-made for specific applications.
- the tape or film according to the present invention may be non-permeable or permeable.
- Non-permeable tapes or films may suitably be used to seal off tissue, e.g. to prevent infection or dehydration.
- Permeable tapes or films may advantageously be employed to staunch bleeding from surgical or traumatic wounds.
- amorphous refers to a material that is a solid and in which there is no long-range order of the positions of the molecules. This lack of order distinguishes amorphous solids from crystalline solids.
- the present invention enables the preparation of an amorphous tape or an amorphous film as the NU-POX component of the cross-linked polymer has excellent amorphous properties. These amorphous characteristics can be retained in the cross-linked polymer especially if the electrophilic cross-linking agent is a low molecular weight cross-linker as defined herein before.
- the cross-linked polymer in the medical product has a glass transition temperature of at least 0° C. and most preferably at least 20° C. Typically, the glass transition temperature of the polymer does not exceed 120° C.
- the adhesive tissue tape or adhesive tissue film of the present invention offers the advantage that it can absorb substantial quantities of water to form a cohesive hydrogel.
- the absorption of water may result in significant swelling of the product.
- the adhesive tissue tape or adhesive tissue film as described herein before does not exhibit significant swelling when it comes into contact with moisture.
- these medical products have a swelling index of between 0% and not more than 100%, preferably of between 0% and not more than 30%, and most preferably of between 0% and not more than 10%.
- Medical products having a low swelling index can suitably be applied in repair of dural defects and spinal cord repair.
- the swelling index preferably does not exceed 50%, most preferably it does not exceed 10%.
- the present invention enables the preparation of an adhesive tissue tape or tissue film having excellent properties without requiring, for instance, support layers.
- the adhesive tissue tape preferably is a single layer tape.
- the adhesive tissue film preferably is a single layer film.
- the medical product is a porous haemostatic product.
- a porous haemostatic product may be prepared, for instance, by converting a viscous solution of NU-POX into a foam and subsequently fixating the foam structure by cross-linking the NU-POX with the electrophilic cross-linking agent. Next, the solvent can be removed and a porous haemostatic product is obtained.
- foaming agents and/or fillers can be employed in this process.
- the haemostatic product so obtained has tissue-adhesive properties due to the presence of non-reacted electrophilic groups as described herein before.
- the haemostatic product may suitably contain a carrier, preferably a water-soluble carrier.
- carriers that may suitably be employed include monosaccharides; di- and oligosaccharides, such as lactose, mannitol, trehalose, erythritol, xylitol, sorbitol, maltitol, isomalt, maltodextrin, cellobiose, glucose, fructose, maltulose, lactulose, maltose, gentobiose, isomaltose, lactitol, palatinitol, dulcitol, ribitol, sucrose, raffinose, gentianose, planteose, verbascose, stachyose, melezitose, inositol; and polysaccharides, such as dextran, starch (amylose, amylopectin), glycogen, cellulose, chit
- the haemostatic product contains 25-75 wt. % of the NU-POX, 25-75 wt. % of the electrophilically activated cross-linking agent and 0-50 wt. % of carrier.
- the present medical product is an implant.
- the cross-linked polymer contained in the implant provides a matrix to support tissue regeneration.
- this is a biodegradable three-dimensional bioresorbable porous construct with attaching properties to bone material and appropriate mechanical properties to guide cellular attachment and subsequent tissue formation.
- the construct is preferably also load bearing, meaning that any fluid component in the implant, or the in-situ formed implant, should be kept as low as possible.
- plasticizers like triacetin or water are needed to render the cross-linking agent and NU-POX extrudable.
- the polymer network comprised in the present implant contains osteoconductive fillers like bone graft materials, including autologous bone, autologous bone particulate, allogenic bone graft material, human cadaver bone, xenograft bone graft material, animal bone, growth factors or synthetic materials such as hydroxyapatite, tricalcium phosphate and bioactive glass.
- osteoconductive fillers like bone graft materials, including autologous bone, autologous bone particulate, allogenic bone graft material, human cadaver bone, xenograft bone graft material, animal bone, growth factors or synthetic materials such as hydroxyapatite, tricalcium phosphate and bioactive glass.
- the medical product of the present invention may suitably be produced in the form of fibres or a fibrous fleece. This may be achieved, for instance, by means of electrospinning or by injecting a NU-POX containing fluid into a solution containing a high concentration of the electrophilic cross-linking agent.
- a fibrous fleece may be produced by employing a polymeric electrophilic cross-linking agent, such as dextran aldehyde, to produce the cross-linked polymer in solution and by subsequently removing the solvent (e.g. water) by means of evaporation.
- Fibrous fleeces can also be produced with the help of an anionic polymeric cross-linking agent such an alginate. This may be done, for instance, by preparing a solution of NU-POX and propylene glycol alginate at low pH and by subsequently increasing the pH, thereby initiating the cross-linking reaction.
- a further aspect of the invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m ⁇ 2, n ⁇ 2 and m+n ⁇ 5; wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate; and wherein the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably at least 5%.
- the covalently cross-linked polymer preferably is a cross-linked polymer as defined herein before.
- kits for producing the biocompatible, cross-linked polymer comprising NU-POX and the electrophilically activated cross-linking agent as defined herein before, wherein the kit comprises separately packaged volumes of the NU-POX and the electrophilic cross-linking agent, and wherein each of the NU-POX and the electrophilic cross-linking agent is present in the form of a fluid or reconstitutable powder.
- the NU-POX and the electrophilic cross-linking agent may be provided in the form of fluid or a powder.
- Providing NU-POX and the cross-linking agent in the form of a fluid or reconstitutable powder allows the NU-POX and the cross-linking agent to undergo a rapid cross-linking reaction.
- the NU-POX is provided in the form of a fluid. More specifically, it is preferred that the NU-POX is contained in a first solvent in a concentration of 1-95 wt. %, preferably of 1.5-20%, most preferably of 2-10%.
- the electrophilic cross-linking agent is preferably also provided in the form of a fluid. Even more preferably, the electrophilically activated cross-linking agent is contained in a second solvent in a concentration of 1-95 wt. %, preferably of 1.5-30%, preferably of 2-10%.
- both the NU-POX and the cross-linking agent are provided in the form of a fluid
- said fluid may be a liquid or a viscous fluid.
- both the NU-POX and the cross-linking agent in the form of a liquid of low viscosity in case both these components are to be applied, for instance, by spraying.
- the NU-POX may need to be diluted substantially.
- a dilute liquid NU-POX solution it is advisable to provide the cross-linking agent in a concentrated solution so as to achieve sufficient cross-linking. This may be achieved by employing a low molecular cross-linking agent as such cross-linking agents can be dissolved in high concentrations without causing high viscosities.
- both the NU-POX and the cross-linking agents may be provided in the form of viscous (gelled) fluids.
- the first solvent and the second solvent are selected from water, polyols, alcohols (e.g. ethanol or iso-propanol) and combinations thereof.
- the volume containing NU-POX and/or the volume containing the cross-linking agent advantageously contain polyol, water or a mixture of both. Furthermore, the latter volumes may suitably be buffered.
- the solvent(s) and buffering system employed in the present kit are suitable chosen so as to achieve an optimum cross-linking rate.
- Polyols that can suitably be employed in the present kit include glycerol, diacetin, triacetin, sorbitol and combinations thereof.
- the first solvent and the second solvent contain 5-50 wt. % water, more preferably 10-30 wt. % water and most preferably 15-20 wt. % water.
- the separately packaged volumes of the NU-POX and the electrophilically activated cross-linking agent may suitably contain a pH modifier.
- the separately packaged volume containing the NU-POX preferably contains an alkalinizing agent that shifts the micro-environmental pH of the NU-POX containing volume to more alkaline conditions in the presence of water or bodily fluids.
- alkalinizing agents include ammonia solution, ammonium carbonate, alkali metal salts including alkali metal carbonates (for instance potassium carbonate and sodium carbonate), potassium hydroxide, sodium hydroxide and sodium borate (borax), tertiary amines such as triethylamine, triethanolamine, other amines like diethanolamine and monoethanolamine, and phosphates.
- alkali metal salts including alkali metal carbonates (for instance potassium carbonate and sodium carbonate), potassium hydroxide, sodium hydroxide and sodium borate (borax), tertiary amines such as triethylamine, triethanolamine, other amines like diethanolamine and monoethanolamine, and phosphates.
- the alkalinizing agent has a pK a at 25° C. of 8-14, in particular of 8.5-11, more particularly of 9 to 11.
- the pH of the separately packaged volume containing NU-POX preferably lies in the range of 7-12, more preferably of 8-11, most preferably of 9-10.
- the separately packaged volumes of the NU-POX and of the cross-linking agent are advantageously contained within a dispensing means from which both volumes can be dispensed simultaneously.
- the two agents may be delivered simultaneously and a cross-linked polymer will form in situ.
- suitable dispensing means include spray dispensers, syringes, and dual syringes.
- Syringes suitably comprise a static mixer and/or a spray nozzle to ensure that the two reactants are mixed together when simultaneously expelled from said syringe.
- At least one of the separately packaged volumes contains a visualization agent to enhance the visibility.
- the visualization agent e.g. a colourant
- a colourant reflects or emits light at a wavelength detectable to a human eye. Because of the inclusion of the visualization agent it is easy for users to accurately apply the reactive mixture.
- suitable colourants include FD&C and D&C colorants, such as FD&C Violet No. 2, FD&C Blue No. 1, D&C Green No. 6, D&C Green No. 5, D&C Violet No. 2; and natural colorants such as beetroot red, canthaxanthin, chlorophyll, eosin, saffron, carmine, indocyanine green, or colored dyes normally found in synthetic surgical sutures. Similarly, dyes such as fluoroscein and methylene blue can be used.
- the visualization agent may or may not become chemically bound to the hydrogel.
- the kit comprises a first biocompatible thin film containing the NU-POX and a second biocompatible thin film containing the electrophilically activated cross-linking agent.
- the two films may suitably be applied after combining the two films on top of each other. Films may suitably have been perforated to increase their specific surface area.
- the biocompatible thin film containing the NU-POX preferably comprises an alkalinizing agent as defined herein before.
- kits for producing a biocompatible, cross-linked polymer comprising NU-POX and the electrophilic cross-linking agent as defined herein before, wherein the kit comprises a powder consisting of particles having a weight averaged mean diameter of 0.01-1000 ⁇ m, said particles including particles containing NU-POX and particles containing the electrophilic cross-linking agent.
- the powder should be readily dispersible in a fluid which may be contained within the same kit.
- the particles comprised in the kit preferably have a weight averaged mean diameter of 0.5-500 ⁇ m and most preferably of 2-300 ⁇ m, said particles including particles containing NU-POX and particles containing the electrophilically activated cross-linking agent.
- the NU-POX and the electrophilically activated cross-linking agent may be contained in the same particles or they may be contained in different particles within the same powder.
- the aforementioned powder may suitably be used as a haemostatic powder that can be stored under ambient conditions.
- the particles comprised in the haemostatic powder may suitably contain a carrier, preferably a water-soluble carrier.
- carriers that may suitably be employed include monosaccharides; di- and oligosaccharides, such as lactose, mannitol, trehalose, erythritol, xylitol, sorbitol, maltitol, isomalt, maltodextrin, cellobiose, glucose, fructose, maltulose, lactulose, maltose, gentobiose, isomaltose, lactitol, palatinitol, dulcitol, ribitol, sucrose, raffinose, gentianose, planteose, verbascose, stachyose, melezitose, inositol; and polysaccharides, such as dextran
- the haemostatic powder contains 25-75 wt. % of the NU-POX, 25-75 wt. % of the electrophilically activated cross-linking agent and 0-50 wt. % of carrier.
- the cross-linked polymer that can be produced with the present kits may or may not have tissue-adhesive properties.
- the kit can be used to produce a cross-linked polymer with tissue-adhesive properties.
- the cross-linking agent contained in the present kit comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the NU-POX.
- the NU-POX and the electrophilically activated cross-linking agent can react to form a cross-linked polymer as defined herein before.
- In-situ cross-linking characteristics of the present kits can be improved by plasticizing NU-POX with a plasticizer selected from the group of triacetin, glycerol, triethylamine and combinations thereof.
- the plasticizer is employed in a concentration of 1-50%, more preferably 3-15% by weight of the NU-POX.
- a particularly preferred embodiment of the present kit produces a cross-linked polymer with tissue adhesive properties.
- This advantageous embodiment may be realized, for instance, by plasticizing NU-POX and the electrophilic cross-linking agent into a single film or tape. Before application as a tissue tape, the latter tape may be combined with another water soluble film containing an activator, or a fluid or a spreadable composition containing an activator.
- the biocompatible cross-linked polymer according to the present invention as well as the NU-POX may advantageously contain an antimicrobial agent covalently bound to one of the oxazoline unit comprised therein. More preferably, the crosslinked polymer or NU-POX contains an antimicrobial agent that is covalently bound to oxazoline units through an amide or imide group. Examples of antimicrobial agents include aminophenols, aminocresol, amino resorcinol and aminonaphtol.
- the antimicrobial agent may suitably be bound to the POX-polymer via a spacer group, such as an alkylene, oxyalkylane or silicone.
- the biocompatible cross-linked polymer may suitably further comprise one or more additive components selected from fillers, oxidants, crosslinkers, microgels, additional polymers, drugs and other therapeutic agents.
- the medical products according to the present invention may advantageously be used in a variety of surgical applications. Examples of these surgical applications are summarized below.
- Ophthalmic surgery Clear corneal cataract surgery; laser in situ keratomileusis (LASIK) surgery; corneal ulcer treatment; corneal transplantation; conjunctival repair; retinal attachment; punctal plugging for treatment of dry eyes; oculoplastics and blepharoplasty (eyelid lifts); vitrectomy closure and attachment of extraocular muscles.
- LASIK laser in situ keratomileusis
- Ear, nose and throat Control of epistaxis (nosebleeds); repair of vocal cord defects; surgery tympanoplasty for repair of perforated eardrum; myringotomy (eardrum incision for drainage) with tube insertion; sinus surgery; nasal reconstructive surgery; tonsillectomy surgery and adenoidectomy surgery.
- Interventional radiology Therapeutic embolization and femoral artery closure during interventional procedures.
- Vascular surgery Arteriovenous fistula repair, aortic aneurysm repair and vascular anastomosis.
- Gynecologic surgery Hysterectomy; myomectomy for uterine fibroid removal; fallopian tube anastomosis; vaginal fistula repair; cervical surgery; ovarian cyst removal; breast biopsy; mastectomy and lumpectomy and management of preterm premature rupture of membranes.
- Urologic surgery Nephrectomy, kidney transplantation; urethral fistula repair; urethral anastomosis; repair for stress urinary incontinence; bladder closure; radical prostatectomy and vasectomy reversal surgery.
- Polymeric coated gas bubbles acting as ultrasound contrast agents can suitably be embedded in the kits or the medical products described herein before.
- Polymeric coated gas bubbles derive their contrast properties from the large acoustic impedance mismatch between blood and the gas contained therein.
- Examples of polymers that can be used to coat these gas bubbles include polylactide, polyglycolide, polycaprolactone, copolymers of polylactide and polyglycolide, copolymers of lactide and lactone, polysaccharide, polyanhydride, polystyrene, polyalkylcyanoacrylate, polyamide, polyphosphazene, poly(methylmethacrylate), polyurethane, copolymers of methacrylic acid and acrylic acid, copolymers of hydroxyethylmethacrylate and methylmethacrylate, polyesters, such as polycarbonates, and protein.
- Preferred polymers are those which are biocompatible and/or biodegradable.
- the polymer is polylactic co-
- Amphiphilic copolymers of NU-POX containing ethyl and amine groups in the alkyl side chain were synthesized by controlled acidic hydrolysis of aquazol 50 (poly(2-ethyl-2-oxazoline (PEtOx), Mw 50,000) to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer (PEtOx-PEI). 12% of the initial 2-ethyl-oxazoline units was hydrolyzed.
- This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl succinyl chloride, followed by the reaction of the methyl ester with ethylenediamine (30 equivalents in the absence of solvent) to yield an amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer.
- the white solid was dissolved in water and freeze-dried, resulting in a white dextran aldehyde (MW 9,000-11,000) of which about 50% of the glucopyranose rings oxidatively cleaved to dialdehydes.
- 2-(2-Methoxycarbonylethyl)-2-oxazoline was prepared following a literature procedure (M. T. Zarka, O. Nuyken, R. Weberskirch, Chem. Eur. J. 2003, 9, 3228-3234, a modified procedure of A. Levy, M. Litt, J. Polym. Sci. A 1968, 6, 1883) followed by cationic ring-opening polymerization yielding the corresponding methylester functionalized homopolymer, poly(2-(2-methoxycarbonylethyl)-2-oxazoline).
- the poly[2-(2-methoxycarbonylethyl)-2-oxazoline] homopolymer was reacted with N-Boc amino ethane amine by dissolving 0.8 g polymer in 2.5 mL N-Boc amino ethane amine followed by 23 hours stirring at 80° C.
- 1 H NMR spectroscopy in CDCl 3 revealed that ⁇ 90% of the methyl ester units were converted into Boc-aminoethyl amido side chains.
- This polymer was further reacted with hydrochloric acid (HCl) by dissolving 850 mg of polymer in dichloromethane (30 mL), which was added dropwise to a HCl solution in ethyl acetate (0.175 mL, 2.98 mmol). After complete addition, the solution was stirred for 6 hours at room temperature.
- 1 H NMR spectroscopy demonstrated the successful formation of the hydrochloric acid salt of amino-ethyl amido side chain functionalized polymer by disappearance of the Boc signal at 1.4 ppm to yield >90% amine-side chain activated poly[2-(amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- the copolymer of 2-ethyl-2-oxazoline containing 25% 2-methoxycarbonyl ethyl-2-oxazoline was functionalized by the reaction of the methyl ester side chains with ethylenediamine (30 equivalents in the absence of solvent) to yield exactly 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- the copolymer of 2-methyl-2-oxazoline containing 25% 2-methoxycarbonyl ethyl-2-oxazoline was functionalized by the reaction of the methyl ester side chains with ethylenediamine (30 equivalents in the absence of solvent) to yield exactly 25% amine-side chain activated poly[2-(methyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- the poly[2-(2-methoxycarbonylethyl)-2-oxazoline] homopolymer was functionalized in two-step approach by partial hydrolysis (25, 50 and 75%) with LiOH of the methylester to the carboxylic acid, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly(NHS-ester-ethyl-oxazoline/methoxycarbonylethyl oxazoline) copolymer (EL-POX).
- the final functionalization degree with NHS was confirmed by UV-Vis spectroscopy and 1 H NMR spectroscopy to be very close to 25, 50 and 75%.
- Copolymers of 2-ethyl-2-oxazoline containing 25, 50 or 75% methylester units and copolymers of 2-methyl-2-oxazoline containing 25, 50 or 75% methylester units were functionalized in two-step approach by quantitative hydrolysis with LiOH of the methylester to the carboxylic acid, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline]polymer (EL-POX).
- the final functionalization with NHS was confirmed by UV-Vis spectroscopy and 1 H NMR spectroscopy to be exactly 25, 50 and 75%.
- LPEI linear poly(ethylene imine)
- LPEI was functionalized in a two-step approach by coupling of succinic anhydride in DMSO, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer.
- the final functionalization with NHS was confirmed by UV-Vis spectroscopy and 1 H NMR to be >95% (EL-POX). This compound was water insoluble.
- LPEI was functionalized in an identical two-step approach with 25, 50 and 75% stoichiometric amounts of NHS, with reference to the carboxylic acid moieties, in the presence of diisopropyl carbodiimide and triethylamine to synthesize resp. 25, 50 and 75% NHS-side chain activated poly(NHS-ester-ethyl-oxazoline/carboxyethyl oxazoline) copolymers.
- the final functionalization degree with NHS was confirmed by UV-Vis spectroscopy and 1 H NMR spectroscopy to be approximately 25, 50 and 75%.
- These EL-POX compounds were water soluble and soluble in 10/90 v/v % water/methanol, resp. water/ethanol mixtures.
- NU-POX can suitably be cross-linked with a NHS-functional polymer.
- Amine-side chain activated poly[2-(ethyl/NHS-ester-ethyl)]-2-oxazoline copolymer (NU-POX) was synthesized by controlled acidic hydrolysis of aquazol 50 (poly(2-ethyl-2-oxazoline (PEtOx), Mw 50,000) to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer (PEtOx-PEI) in which 12% of the initial 2-ethyl-oxazoline units was hydrolyzed.
- This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl succinyl chloride in the presence of triethylamine, followed by the reaction of the formed methyl ester side chain with ethylenediamine to yield an amine-side chain activated poly(2-ethyl/amino-ethyl-amide-ethyl)-2-oxazoline copolymer.
- This NU-POX was turned into an EL-POX by reacting the amine with maleic anhydride to yield maleimide-side chain activated poly(2-ethyl/maleimide-ethyl-amide-ethyl)-2-oxazoline copolymer.
- TCEP tris(2-carboxyethyl)phosphine
- POX containing >95% carboxylic acid moieties in the alkyl side chain was synthesized as described in Example A. This POX was activated with 2-thiazoline-2-thiol in the presence of diisopropyl carbodiimide and triethylamine to synthesize 2-thiazoline-2-thioester-side chain activated poly[2-(thiazoline-thioester-ethyl)-2-oxazoline]polymers (EL-POX). The identity of this EL-POX was confirmed by 1 H NMR.
- Amphiphilic copolymers of NU-POX containing ethyl and NH 2 groups in the alkyl side chain were synthesized as described in example 1:12% of the initial 2-ethyl-oxazoline units were hydrolyzed.
- NU-POX can suitably be cross-linked with a thiazoline-functional polymer.
- EL-POX containing >95% N-hydroxysuccinimide (NHS) groups in the alkyl side chain was synthesized as described in Example A. This EL-POX was reacted with 2-(1,3-Dioxolan-2-yl)ethanamine to synthesize a polymer containing >95% protected aldehyde functionality. The polymer was deprotected using a previously described procedure (Taubmann, C., Luxenhofer, R., Cesana, S. and Jordan, R. (2005), First Aldehyde-Functionalized Poly(2-oxazoline)s for Chemoselective Ligation. Macromol. Biosci., 5: 603-612.) which yielded the >95% aldehyde functionalized polymer (EL-POX). The identity was confirmed by 1 H-NMR and 13 C-NMR.
- NU-POX can suitably be cross-linked with an aldehyde-functional polymer.
- NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline] copolymer containing 50% NHS units and 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer were prepared as described in Example A.
- the NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline] copolymer, containing 50% NHS units was dissolved in ethanol (absolute).
- the 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in ethanol (absolute).
- glycerol plasticizer
- the burst pressure of this formulation was tested in the following manner.
- Collagen casing of consistent properties and thickness (sausage casing, Nippi Casing Co. (#320),4) was used (substrate). Sections of the substrate were washed in deionized water to remove glycerine and soaked in fresh deionized water for five minutes. A 3 mm circular incision was cut into the substrate, which was then secured to a burette in such a manner that simulated body fluid could be forced out under measurable pressure via the circular incision.
- the amorphous tape was put onto the secured substrate to form a seal. After a few minutes, the pressure of the simulated body fluid was increased to the point that the seal burst (burst pressure). The burst pressure was found to be adequate for a sealing tape.
- the NHS:amine ratio in this film was 5:1.
- a syringe comprising two separate reservoirs and a static mixing unit to mix the contents of the reservoirs when the two reservoirs are emptied simultaneously was filled with two viscous fluids.
- NU-POX NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer
- EL-POX NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer
- the NU-POX was weighed accurately into a vessel containing water and the contents (50/50 w/w) were mixed well.
- the first reservoir of the syringe was filled with the NU-POX gel taking care to exclude large air bubbles.
- the second reservoir of the syringe was filled with an aqueous EL-POX solution that had been prepared in an identical manner.
- the amine-NHS ratio was 1:5.
- Both the static mixer and plunger were attached and the two gels were extruded through the static mixture to form a homogenous, clear, cross linked polymeric phase with an initial setting time of less than 1 minute.
- Both the static mixer and plunger were attached and the two gels were extruded through the static mixture to form a homogenous, clear, cross linked polymeric phase with an initial setting time of less than 1 minute.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1 (NU-POX) and 75% NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer was synthesized as described in example A (EL-POX).
- N-hydroxy succinimide end capped PEG powder 20,000 Da [PEG-NHS] was obtained form a DuraSeal, Dural Sealant System and trilysine was purchased from Sigma.
- the number of electrophilic groups/molecule of EL-POX was approximately 375 and the number of electrophilic groups/molecule of PEG-NHS was approximately 4.
- the number of nucleophilic groups/molecule of NU-POX was approximately 29 and the number of electrophilic groups/molecule of trilysine was 4.
- NU-POX and the PEG-NHS were dissolved in water containing the same amount (w/w) of trehalose, snap freezed with the aid of liquid nitrogen and freeze dried overnight yielding respectively, NU-POXt and PEG-NHSt.
- the EL-POX was dissolved in water containing the same amount (w/w) of trehalose including citrate buffer (pH 5.5 after reconstitution in water), snap freezed with the aid of liquid nitrogen en freeze dried overnight yielding EL-POXt.
- Trilysine was dissolved in water containing a 100 fold amount (w/w) of trehalose, snap freezed with the aid of liquid nitrogen en freeze dried overnight yielding trylisine-t.
- formulations A and B exhibited adequate haemostatic properties. Best results were obtained for the formulation containing a combination of NU-POX and EL-POX, indicating that the cross-linking imparted improved haemostatic properties. Furthermore, it was found that the cross-linking yielded a stronger gel. Without buffer, experiment B lead to a gel in about 15 minutes.
Abstract
Description
- The invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting nucleophilically activated polyoxazoline (NU-POX) with an electrophilically activated cross-linking agent.
- Also provided is a kit for producing a biocompatible, cross-linked polymer from NU-POX with an electrophilically activated cross-linking agent.
- The invention further provides a medical product comprising at least 1% by weight of dry matter of said cross-linked polymer. Examples of such medical products are medical implants including bone implants, soft tissue implants, adhesive implants, coatings on implants, sutures, adhesive tissue sealants and adhesive tissue tapes.
- Tissue adhesives have many potential medical applications, including wound closure, supplementing or replacing sutures or staples in surgical procedures, adhesion of synthetic onlays or inlays to the cornea, drug delivery devices, and as anti-adhesion barriers to prevent post-surgical adhesions.
- Conventional tissue adhesives include fibrin sealants, cyanoacrylate based sealants, and other synthetic sealants and polymerizable macromers. Some of these conventional sealants are only suitable for a specific range of adhesive applications. For example, cyanoacrylate-based adhesives have been used for topical wound closure, but the release of toxic degradation products limits their use for internal applications. Fibrin-based adhesives are expensive, often need refrigerated storage, are slow curing, have limited mechanical strength, and pose a risk of viral infection.
- For certain applications, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, abdominal hernias, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; plugging to seal a fistula or the punctum, slow degrading tissue adhesives are needed.
- The last decade, several types of (semi)synthetic hydrogel tissue adhesives have been developed, which have improved adhesive properties and are non-toxic. Most of these hydrogel tissue adhesives, like DuraSeal®, are chemically based on a process called PEGylation used in polymer-modified therapeutics with reactive polyethylene glycol (PEG) precursors like, for instance, PEG-succinimidyl glutarate. These hydrogel tissue adhesives, based on PEGylation, typically swell or dissolve away too quickly, or lack sufficient cohesion (interconnecting mechanical strength), thereby decreasing their effectiveness as surgical adhesives. Moreover, to apply these hydrogel tissue adhesives, dual syringe spray technology may be needed, which demands extensive sample preparation from freeze dried starting materials. Finally, the properties of such PEG-based materials cannot be easily controlled and the number of NHS-groups is limited to the number of chain ends; possibly comprising multiple NHS groups per chain end resulting in a high NHS group density rather than regularly distributed groups.
- WO 2002/062276 describes a hydrogel tissue sealant comprising a star-shaped PEG-succinimidyl glutarate precursor, also known as star-PEG-NHS or star-PEG-NS or star-SG-PEG or star-PEG-SG, that reacts with a trilysine precursor. The star-SG-PEG precursor may be reconstituted in pH 4 phosphate, while the trilysine precursor may be reconstituted in pH 8 borate buffer. Upon mixing, covalent amide bonds between amines of the trilysine precursor and NHS-activated terminal carboxylate groups of the star-SG-PEG precursor are formed.
- WO 2010/059280 describes an anhydrous fibrous sheet comprising a first component of fibrous polymer, said polymer containing electrophilic groups or nucleophilic groups, and a second component capable of crosslinking the first component when said sheet is exposed to an aqueous medium to form a crosslinked hydrogel that is adhesive to biological tissue. The examples of the international patent application describe the preparation of fibrous sheets comprising dextran aldehyde and multi-arm polyethylene glycol amine.
- WO 00/33764 describes a method for preparing a biocompatible crosslinked polymer, comprising:
-
- providing a biocompatible small molecule crosslinker having n crosslinker functional groups, wherein n is two or more, and wherein the crosslinker functional groups are either electrophilic or nucleophilic;
- dissolving the biocompatible small molecule crosslinker in a first solvent to form a crosslinker solution;
- providing a biocompatible functional polymer having m functional polymer functional groups, wherein m is two or more and the sum of n and m is five or more, and wherein the functional polymer functional groups are nucleophilic if the crosslinker functional groups are electrophilic, and the functional polymer functional groups are electrophilic if the crosslinker functional groups are nucleophilic;
- dissolving the biocompatible functional polymer in a second solvent to form a functional polymer solution; and
- combining the crosslinker and functional polymer solutions to react the crosslinker functional groups with the functional polymer functional groups.
Polyoxazoline is nowhere mentioned in WO 00/33764.
- WO 2005/109248 describes cross-linked polymeric compositions of hydrolyzed poly(2-alkyl-2-oxazoline) and the use of these cross-linked polymeric compositions in color ink-jet ink.
- WO 2009/043027 describes multiarmed, monofunctional derivatives of polyoxazolines, as well as conjugates of such polyoxaline derivatives with drugs.
- Preparation of a cross-linked, polymer by reacting nucleophilically activated polyoxazoline (NU-POX) with an electrophilically activated cross-linking agent has been described by Luxenhofer (Thesis: Novel Functional Poly(2-oxazoline)s as Potential Carriers for Biomedical Applications, Technische Universitat München (2007)). A poly(-oxazoline) comprising 20 units of 2-methyl-2-oxazoline and 5 units of 2-aminoethyl-2-oxazoline was cross-linked with hexamethylene diisocyanate. Due to the high reactivity of isocyanates towards water, the hydrogel preparation had to be performed in the absence of water. As a good and water compatible (for subsequent swelling) solvent for poly(-oxazoline)s acetonitrile was chosen. The cross-linker was directly added to the solvent which was subsequently added to the lyophylized polymer. After 10 min 1.5 mL of water was added upon which the hydrogel immediately swelled.
- Chujo et al. (Reversible Gelation of Polyoxazoline by Means of Diels-Alder Reaction, Macromolecules, 1990(23), 2636-2641) describes the preparation of a polyoxazoline hydrogel by means of intermolecular Diels-Alder reaction between furan-modified poly(N-acetylethylenimine) (PAEI) and maleimide-modified PAEI, which were synthesized from the partially hydrolyzed PAEIs by the reaction with furan- or maleimidecarboxylic acid, respectively, in the presence of dicyclohexylcarbodiimide.
- It is of interest to expand the range of polymers having implant or tissue sealant applications, especially to provide polymers having properties not possessed by PEG-based polymers while being similarly biocompatible.
- The inventors have discovered that a polymer having excellent implant and/or sealing characteristics can be obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) and at least two nucleophilic groups with a cross-linking agent that comprises at least two electrophilic groups, said cross-linking agent not being an electrophilically activated polyoxazoline.
- Thus, the invention provides a biocompatible medical product comprising a covalently cross-linked, polymer that is obtained by reacting a NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5, and wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate.
- Examples of biocompatible medical products according to the present invention include implants, tissue sealants, adhesive tissue tape, suture materials, polymer coated stents and haemostatic materials.
- The cross-linked polymer of the present invention provides a number of beneficial properties:
-
- Mechanical properties of the cross-linked polymer can be manipulated effectively by controlling the level and nature of alkyl side chain and/or end-group functionalization and the polymer chain length. Cationic 2-oxazoline polymerization can suitably be used to incorporate a large number of activated groups in the alkyl side chains of the POX polymer;
- Adhesive properties of the cross-linked polymer can be varied by using different electrophilic cross-linking agents and by varying the amount of electrophilic cross-linking agent that is used in the preparation of the cross-linked polymer.
- Cohesiveness of the cross-linked polymer is determined largely by the number/density of cross-links within the polymer. The number of cross-links in the polymer can be varied within wide ranges by incorporating different amounts of activated groups in the side chains of the POX;
- The swelling index of the cross-linked polymer can be controlled by manipulating the number of cross-links and the size of the side chains in the POX;
- Implants made of the cross-linked polymer are an ideal drug depot for local drug delivery. The release of drugs, such as antibiotics, growth factors like VEGF and osteogenic factor (BMP-2), may be sustained by slow diffusion from the interconnecting network depending on the nature of the alkyl side chains and the density of cross links within the network and the degradability;
- Biodegradability of the cross-linked polymer can be controlled effectively by incorporating hydrolysable groups, such as esters or carbonates, into the copolymers. It is further influenced by the number of internal cross links. Thus, it is possible to fine tune the biodegradability of the polymer to the intended use;
- Based on end capped POX-NHS in research for drug delivery, POX seems to have similar or even better stealth and antifouling behaviour than PEG. For renal clearance the POX should preferably have a Mw of 30,000 or less.
- Another aspect of the invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate; and wherein the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably at least 5%.
- Yet another aspect of the invention relates to a kit for producing a biocompatible, cross-linked polymer, said kit comprising the NU-POX and the electrophilically activated cross-linking agent described herein before. This kit may suitably be used to deliver bone substitute materials, anti-adhesive implants (films), adhesive implants (for instance a tissue sealant for closing arterial puncture sites, or for embolization or to treat urinary incontinence).
- The rate at which cross-linking occurs when the NU-POX and the electrophilically activated cross-linking agent are brought together can be controlled effectively by including non-inert fluids, such as water (various pH), alcohols and/or polyols.
- The NU-POX component of the biocompatible medical product of the present invention offers the following advantages:
-
- Due to its hydrophilic/hydrophobic balance, NU-POX can be soluble in organic fluids like ethanol and dichloromethane as well as in water.
- NU-POX has excellent amorphous properties with a glass transition temperature markedly higher compared to, for instance, polyethylene glycol.
- NU-POX has film forming capabilities and is easy to plasticize with limited amounts of plasticizers.
- An advantage of NU-POX over nucleophilically activated PEG is the possibility to incorporate different and also functionalized groups along the chain in order to tune the polymer properties for specific applications;
- Another advantage of NU-POX over nucleophilically activated PEG is that NU-POX may be co-polymerized, allowing the preparation of a cross-linked copolymer with mechanical characteristics that can vary within a wide range;
- NU-POX provides a protective environment for electrophilic groups in the implant when it is not exposed to water or bodily fluids.
- Accordingly, one aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) with an electrophilically activated cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups, and said electrophilically activated cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds, wherein m≧2, n≧2 and m+n≧5, wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate.
- The term “polyoxazoline” as used herein refers to a poly(N-acylalkylenimine) or a poly(aroylalkylenimine) and is further referred to as POX. The term “polyoxazoline” as used herein also encompasses POX copolymers.
- The terminology “electrophilically activated cross-linking agent” as used herein refers to a polyoxazoline containing at least 2 electrophilic groups, notably electrophilic groups selected from electrophilic groups contained in the EL-POX are selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato, isocyano, epoxides, activated hydroxyl groups, olefins, glycidyl ethers, carboxyl, succinimidyl ester, succinimidyl carbonate, succinimidyl carbamates, sulfosuccinimidyl ester, sulfosuccinimidyl carbonate, maleimido(maleimidyl), ethenesulfonyl, imido esters, aceto acetate, halo acetal, orthopyridyl disulfide, dihydroxy-phenyl derivatives, vinyl, acrylate, acrylamide, iodoacetamide and combinations thereof.
- The terminology “pendant nucleophilic group” refers to a nucleophilic group that is comprised in a side chain, e.g. an alkyl or aryl side chain, of the POX polymer, as opposed to a nucleophilic group that is located at a terminus of the POX polymer chain. It should be understood that a particular side chain of the POX polymer may suitably contain more than one nucleophilic group, in which case each nucleophilic group within that particular side chain counts as a pendant nucleophilic group.
- The term “amine groups” as used herein refers to primary or secondary amine groups.
- Whenever the NU-POX or the cross-linked polymer of the present invention is characterized on the basis of the presence of a certain number of particular groups or bonds per 100 monomers it should be understood that this does not imply that the polymer contains at least 100 monomers. For example, a NU-POX comprising 80 monomers and 8 pendant groups contains 10 pendant groups per 100 monomers. Likewise, if a NU-POX contains 80 monomers and it is specified that this polymer contains, for instance, at least x pendant groups per 100 monomers, this criterion is met if this particular polymer contains on average at least 0.8x pendant groups.
- The NU-POX of the present invention is a nucleophilically activated version of a polyoxazoline polymer whose repeating units are represented by the following formula (I):
-
(CHR1)mNCOR2 - R2, and each of R1 independently being selected from H, optionally substituted C1-22 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted aryl; and m being 2 or 3. The invention also encompasses the use of polyoxazolines copolymers that comprise two or more different repeating units that are represented by formula (I).
- Preferably, R1 and R2 in formula (I) are selected from H and C1-22 alkyl, even more preferably from H and C1-4 alkyl. R1 most preferably is H. The integer m in formula (I) is preferably equal to 2.
- In a preferred embodiment, the polyoxazoline employed in accordance with the present invention is a polymer, more preferably a homopolymer, of 2-alkyl-2-oxazoline, said 2-alkyl-2-oxazoline being selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-propyl-2-oxazoline, and combinations thereof. Even more preferably, the 2-alkyl-oxazoline is selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline and combinations thereof. Most preferably, the 2-alkyl-2-oxazoline is 2-methyl-oxazoline.
- In case the electrophilic cross-linking agent is an isocyanate, the NU-POX employed in accordance with the present invention advantageously contains at least 40, even more preferably at least 50 and most preferably at least 100 (monomeric) oxazoline units.
- According to a particularly preferred embodiment at least one of the two reactants employed in the cross-linked polymer of the present invention, i.e. the NU-POX and/or the electrophilic cross-linking agent, is a polymer having a degree of polymerization of at least 20, more preferably at least 30, even more preferably of least 50 and most preferably of at least 100.
- The use of a NU-POX having a high degree of polymerization enables the preparation of resilient cross-linked polymers that are ideally suited for application in tissue sealants, implants etc. Accordingly, in a preferred embodiment, the NU-POX contains at least 20, even more preferably at least 30, yet more preferably at least 50 and most preferably at least 100 (monomeric) oxazoline units
- The NU-POX employed in accordance with the present invention contains pendant nucleophilic groups, terminal nucleophilic groups, or a combination thereof. Preferably, at least one of the m nucleophilic groups in the NU-POX being part of the biocompatible cross-linked polymer according to any of the foregoing is a pendant nucleophilic group. Typically, said NU-POX contains 3 to 50 pendant nucleophilic groups per 100 monomers in the cross-linked polymer, more preferably 5 to 20 pendant electrophilic groups per 100 monomers in the cross-linked polymer.
- According to a particularly preferred embodiment of the invention, the cross-linked polymer has tissue-adhesive properties. Whenever the terminology “tissue adhesive” is used herein in relation to the cross-linked polymer, it means that the unreacted electrophilic groups contained in the cross-linked polymer are capable of reacting with nucleophilic (e.g. amine or thiol) groups that are naturally present in tissue to form covalent bonds. Preferably, the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably by at least 5%, even more preferably by at least 10% and most preferably by at least 20%.
- The tissue adhesive properties of the cross-linked polymer can be controlled very effectively by manipulating the number of non-reacted electrophilic groups in the cross-linked polymer. Generally speaking, the higher the number of non-reacted electrophilic groups, the stronger the adhesion. Preferably, the cross-linked polymer comprises, per 100 NU-POX monomers, at least 2, more preferably at least 5 and most preferably at least 10 electrophilic groups of the electrophilic cross-linking agent that have not reacted with a nucleophilic group of the NU-POX.
- Preferably, the m nucleophilic groups on NU-POX are selected from amine groups, thiol groups, phosphine groups and combination thereof. Even more preferably, the nucleophilic groups are selected from amine groups, thiol groups and combinations thereof.
- According to one preferred embodiment, the nucleophilic groups present in the NU-POX are amine groups. An amine functionalized NU-POX can suitably be derived from a homopolymer or copolymer of cysteamine modified 2-alkenyl-2-oxazoline or 2-t-BOC-aminoalkyl-2-oxazoline and 2-alkyl-2-oxazoline. The cysteamine modified 2-alkenyl-2-oxazoline comprised in the copolymer is preferably selected from 2-butenyl-2-oxazoline, and combinations thereof. The 2-alkyl-2-oxazoline is preferably selected from 2-ethyl-2-oxazoline, 2-methyl-2-oxazoline, 2-propyl-2-oxazoline and combinations thereof. The amine moieties can also be introduced by partial hydrolysis of POX followed by alkylation or amidation of the resulting secondary amine groups in the polymer chain.
- According to another preferred embodiment, the m nucleophilic groups present in the NU-POX are thiol (sulfohydryl) groups. Even more preferably, the NU-POX is a poly(2-alkyl-2-oxazoline) with thiol terminal groups that have been introduced by endcapping the polymerization with a multifunctional initiator with potassium xanthogenate followed by aminolysis to get the free thiol groups. Alternatively, the thiol moieties are introduced into the side chains of the NU-POX by copolymerization of a protected thiol containing monomer or by modification of acid, amine or alkenyl side chains or by modification of the backbone secondary amines resulting from partial hydrolysis. The 2-alkyl-2-oxazoline is preferably selected from 2-ethyl-2-oxazoline, 2-methyl-2-oxazoline, 2-propyl-2-oxazoline and combinations thereof.
- According to a preferred embodiment, the NU-POX contains oxazoline units containing a nucleophilic group and oxazoline units containing no nucleophilic group in a molar ratio that lies within the range of 1:50 to 1:1, more preferably in a molar ratio that lies within the range of 3:100 to 1:2.
- The NU-POX employed in accordance with the present invention typically has a molecular weight in the range of 1,000 to 100,000 g/mol, more preferably of 5,000 to 50,000 and most preferably of 10,000 to 30,000 g/mol.
- The NU-POX employed in accordance with the present invention can be a homopolymer or a copolymer. Most preferably, NU-POX is a copolymer.
- The electrophilically activated cross-linking agent employed in accordance with the present invention contains a backbone that carries or is substituted with n≧2 electrophilic groups. The backbone preferably is chosen from the group consisting of polymers, diacids, triacids or higher acids. The backbone of the electrophilically activated cross-linking agent is not a polyoxazoline.
- In a preferred embodiment the backbone of the electrophilically activated cross-linking agent is selected from the group of polymers consisting of polyesters, polyolefins, polystyrenes, polycarbonates, polyamides, polyacetates, poly(alkylene oxalates), polyanhydrides, poly iminocarbonates, polyoxaesters, polyorthoesters, polyphosphazenes, polyphosphoesters, polyethers, polyetheresters, polyacrylamides, polyimides, polyphenylenes, polysilanes, polysiloxanes, polybenzimidazoles, polybenzothiazoles, polysulfides, polyesteramides, polyetheramides, polyamines, polyetheramines, polyarylene vinylenes, polyether ketones, polyurethanes, polysulfones, polyacrylates, polymethacrylates, polysaccharides, glycosaminoglycans, polypeptides, and combinations thereof. Typically, these polymers have a molecular weight in the range of 1,000-100,000.
- Even more preferably, the backbone of the electrophilically activated cross-linking agent is selected from the group of polymers consisting of agar, starch, pullulan, inulin, levan, silk, fibronectin, pectin, cellulose (e.g. carboxymethyl cellulose, hydroxyethyl cellulose, oxidized cellulose or methyl cellulose), collagen, elastin, gelatin, albumin, fibrin, fibrinogen, dextran, methyl cellulose, hyaluronic acid, chondroitin sulfate, keratosulfate, heparan sulfate, dermatan sulfate, alginic acid, chitosan, chitin, heparin, polyvinyl alcohol, polyethylene glycol and combinations thereof. The backbone of the electrophilically activated cross-linking agent may suitably be selected from the group of polysaccharides consisting of dextran (e.g. carboxymethyldextran), starch, agar, cellulose pullulan, inulin, levan, and hyaluronic acid. In accordance with a particularly advantageous embodiment, the latter polysaccharides are employed in a (partially) oxidized form.
- Most preferably, the electrophilic cross-linking agent is selected from the group of polymers consisting of dextran, collagen, gelatin (gelfoam), alginic acid and polyethylene glycol.
- In another preferred embodiment the electrophilic cross-linking agent employed in the biocompatible cross-linked polymer is a low molecular weight electrophilic cross-linker having a molecular weight of 80-1000 g/mol, preferably of 100-500 g/mol. Examples of low molecular cross-linking agents that may suitably be employed include multialdehydes, multimaleimides, multi-activated esters and combinations thereof (here the term ‘multi’ means at least two). According to a preferred embodiment, the low-molecular cross-linker has a backbone consisting of an acid selected from the group consisting of diacids, triacids and higher acids modified with N-hydroxysuccinimide (NHS) or sulfo-NHS. Even more preferably, the acid-based cross-linking agent is selected from diacids, triacids and combinations thereof. Non-limiting examples of diacids and triacids that may be employed are diglycolic acid, oxalic acids, malonic acids, malic acid, tartaric acid, maleic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, phthalic acid, tetrahydrophthalic acid, hexahydrophthalic acid, trimesic acid, mellitic acid, isophthalic acid, terephthalic acid, citric acid, isocitric acid, aconitic acid, tricarballylic acid and trimesic acid. Most preferably, the acid that forms the backbone of the electrophilic cross-linking agent is selected from triacids, most preferably citric acid.
- Preferably, the acid-based cross-linking agent is selected from the group of amino carboxylic acids. Non-limiting examples of amino carboxylic acids that may be employed are: Fura-2, iminodiacetic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylene triamine pentaacetic acid, ethylene glycol tetraacetic acid, (1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and oligopeptides based on glutamic acid and/or aspartic acid.
- According to a particularly preferred embodiment, the electrophilic cross-linking agent is a polymer having a molecular weight in excess of 1000 g/mol, more preferably of 2000-10000 g/mol and most preferably of 5000-50000 g/mol. The use of polymeric electrophilic cross-linking agents offers the advantage that the excess electrophilic groups are further away from the crosslinking points thereby increasing their mobility and ability to couple to tissue.
- The electrophilic groups contained in the cross-linking agent preferably are highly reactive towards the nucleophilic groups contained in the NU-POX, preferably at ambient and/or physiological conditions.
- The electrophilic groups present in the cross-linking agent are preferably selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato (isothiocyanato), epoxides, activated hydroxyl groups, glycidyl ethers, carboxyl, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates, maleimides, imido esters, orthopyridyl disulfide, dihydroxy-phenyl derivatives, vinyl, acrylate, acrylamide, iodoacetamide, halo acetals, orthopyridyl disulfide, vinyl sulfone, dihydroxyphenyl derivatives, iodoacetamide, and combinations thereof.
- Examples of sulfonate esters that can be used as electrophilic groups include mesylate, tosylate, nosylate, triflate and combinations thereof. Examples of activated hydroxyl groups include hydroxyl groups that have been activated with an activating agent selected from p-nitrophenyl chlorocarbonates, carbonyldiimidazoles (e.g. 1,1-carbonyl diimidazole) and sulfonyl chloride.
- Examples of succinimidyl derivatives that may be employed include succinimidyl glutarate, succinimidyl propionate, succinimidyl succinamide, succinimidyl carbonate, disuccinimidyl suberate, bis(sulfosuccinimidyl) suberate, dithiobis(succinimidylpropionate), bis(2-succinimidooxycarbonyloxy) ethyl sulfone and 3,3′-dithiobis(sulfosuccinimidyl-propionate). Examples of sulfosuccinimidyl derivatives that can be used include sulfosuccinimidyl(4-iodoacetyl)aminobenzoate, bis(sulfosuccinimidyl) suberate, sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, dithiobis-sulfosuccinimidyl propionate, disulfo-succinimidyl tartarate; bis[2-(sulfo-succinimidyloxycarbonyloxyethyl sulfone)], ethylene glycol bis(sulfosuccinimiclylsuccinate), dithiobis-(succinimidyl propionate). Examples of dihydroxyphenyl derivatives include dihydroxyphenylalanine, 3,4-dihydroxyphenylalanine (DOPA), dopamine, 3,4-dihydroxyhydroccinamic acid (DOHA), norepinephrine, epinephrine and catechol.
- According to one preferred embodiment, the m≧2 nucleophilic groups of the NU-POX are amine groups, preferably primary amine groups, and the n≧2 electrophilic groups comprised in the electrophilically activated cross-linking agent are selected from carboxylic acid esters, sulfonate esters, phosphonate esters, thioesters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanato, thioisocyanato, epoxides, activated hydroxyl groups, glycidyl ethers, carboxyl, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates, imido esters, dihydroxy-phenyl derivatives, and combinations thereof. Even more preferably, the electrophilic groups contained in the cross-linking agent are selected from aldehydes, succinimidyl esters, succinimidyl carbonates, succinimidyl carbamates, imido esters, dihydroxyphenyl derivatives and combinations thereof. Most preferably, the electrophilic groups are selected from the group of N-hydroxysuccinimide esters, aldehydes, dihydroxyphenyl derivatives and combinations thereof.
- According to another preferred embodiment, the m≧2 nucleophilic groups of the NU-POX are thiol groups and the n≧2 electrophilic groups contained in the electrophilically activated cross-linking agent are selected from halo acetals, orthopyridyl disulfide, maleimides, vinyl sulfone, dihydroxyphenyl derivatives, vinyl, acrylate, acrylamide, iodoacetamide, succinimidyl esters, succinimidyl carbonate, succinimidyl carbamates, sulfosuccinimidyl esters, sulfosuccinimidyl carbonates and combinations thereof. More preferably, the electrophilic groups are selected from succinimidyl esters, halo acetals, maleimides, or dihydroxyphenyl derivatives and combinations thereof. Most preferably, the n≧2 electrophilic groups are selected from maleimides or dihydroxyphenyl derivatives and combinations thereof.
- According to a particularly preferred embodiment the m≧2 nucleophilic groups comprised in the NU-POX component of the cross-linked polymer are capable of reacting with the n≧2 electrophilic groups of the cross-linking agent under ambient and/or physiological conditions to form covalent bonds.
- Non-reacted electrophilic groups in the cross-linked polymer of the present invention impart tissue adhesive properties to the polymer as they can react with nucleophilic groups (e.g amino groups and thiol groups) that are naturally present in tissue. Thus, when a cross-linked polymer containing non-reacted electrophilic groups is applied to tissue, the non-reacted electrophilic groups can react with nucleophilic groups of the tissue, thereby creating strong adhesion between the polymer and the tissue. The ability to form cross-links at ambient temperature is especially advantageous if the cross-linking should occur in situ during e.g. surgery. Typically, at 35° C. and 1 atm., the cross-linking reaction between the NU-POX and the cross-linking agent is completed within 30 minutes, preferably within 10 minutes, more preferably within 5 minutes, most preferably within 2 minutes.
- The ability of the (dry) cross-linked polymer to swell when contacted with water, next to its overall hydrophobicity, depends strongly on the level of cross-linking. The more cross-linking, the lower the swelling index. Preferably, the polymer contains, per 100 monomers, not more than 50, more preferably not more than 20 and most preferably not more than 10 of covalent bonds that have been formed by the reaction between the nucleophilic groups of the NU-POX and the electrophilic groups of the cross-linking agent. Typically, this number of covalent bonds is at least 2 per 100 monomers.
- NU-POX comprising pendant nucleophilic groups can suitably be prepared by cationic polymerization of 2-oxazoline monomers initiated by various electrophilic species, for example alkyl halides, sulfonic esters, strong acids and others. POX-derivatives containing activated groups in the side chain can be prepared directly from the 2-oxazoline monomer containing the required (protected) group, or by a polymer analogous reaction of polymer precursors. Synthesis of a functional group at the POX terminus is, for instance, described by Anna Mero et. al. (Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: Suitable alternatives to PEG-conjugates?, Journal of Controlled Release 125 (2008) 87-95).
- NU-POX containing ethyl and amino (—NH2) groups in the alkyl side chain can be synthesized by reaction of poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer with cysteamine, by copolymerization of a protected amine monomer with 2-ethyl-2-oxazoline or by partial hydrolysis of POX followed by post-modification.
- NU-POX containing ethyl and thiol (—SH) groups in the alkyl side chain can be prepared in a similar fashion by reaction of poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer with an excess of ethanedisulfide, by copolymerization of 2-ethyl-2-oxazoline with a monomer bearing a protected thiol group or by partial hydrolysis of POX followed by post-modification.
- In case the present cross-linked polymer is obtained by cross-linking an NHS-activated cross-linking agent, biodegradability can range from essentially non-degradable to easily degradable. Biodegradability can be improved by incorporation of an ester link that is more readily hydrolyzed than the secondary amides resulting from reactions between the NHS-ester and amines. The ester groups are directly hydrolyzed in aqueous environment by reaction with water while the secondary amides are mainly hydrolyzed by enzymatic degradation that will be very slow in the cross-linked network, at neutral pH.
- Cationic polymerization enables the synthesis of copolymers with a predefined number of activated groups. Furthermore, cationic 2-alkyl-2-oxazoline polymerization can be used to incorporate a large number of active groups as these active groups are coupled to the numerous alkyl side chains of the POX. This again makes it possible to produce highly cross-linked polymers with excellent cohesive properties as well as outstanding adhesive properties in case the cross-linked polymer has a high density of unreacted electrophilic groups.
- In addition, cationic polymerization allows the incorporation of various functional groups in the side-chain and/o terminus, thereby enhancing the versatility of the POX polymer system.
- The synthesis of a copolymer containing a predefined number of activated groups per copolymer can be carried out as follows: a copolymer is synthesized by cationic polymerization of ETOX and BUTOX, as described previously, to yield a poly[2-(ethyl/3-butenyl)-2-oxazoline copolymer. Upon functionalization of the activated side chains with e.g. cysteamine, primary amine groups are introduced. In case the initial ETOX/BUTOX molar ratio is 90/10, the percentage of reactive groups per poly[2-(ethyl/3-butenyl)]-2-oxazoline copolymer, will be 10%. Increasing the BUTOX in the initial 90/10 ETOX/BUTOX mixture will eventually result in a higher percentage of amino groups, i.e. more than 10%. The exact number of incorporated amino groups can be controlled by the ratio of monomer to initiator that determines the length of the polymer. For example, using an ETOX/BUTOX ratio of 90/10 and a monomer to initiator ratio of 100:1 yields polymers with 100 repeat units comprising 10 amino groups. When the monomer to initiator ratio is changed to 200:1 the resulting copolymer will have 20 amino groups with the same ETOX/BUTOX ratio.
- The cross-linked polymer of the present invention may be biodegradable or non-biodegradable. Preferably, the polymer is biodegradable.
- The medical product of the present invention preferably comprises at least 25% and most preferably 50-100% by weight of dry matter of a cross-linked polymer as defined herein before. Preferred examples of such medical products include implants, tissue sealants, adhesive tissue tape, adhesive tissue film (sheet), suture material, polymer coated stents and haemostatic (porous) materials.
- The medical product may suitable contain other pharmaceutically acceptable components besides the cross-linked polymer. For instance, it may be advantageous to incorporate a polymer that is not part of the cross-linked polymer. Examples of such polymers include aphipathic polymers (such as collagen, gelatin and fibrin), neutral biopolymers (such as dextran and agarose) or ionic polymers. The ionic polymers may be cationic (such as chitin or chitosan) or anionic. A suitable anionic polymer is, for example, a synthetic polymer, biopolymer or modified biopolymer comprising carboxy, sulfo, sulfato, phosphono or phosphato groups or a mixture thereof, or a salt thereof, for example a biomedical acceptable salt. Examples of synthetic anionic polymers are: a linear polyacrylic acid (PAA), a branched polyacrylic acid, for example a Carbophil® or Carbopol® type from Goodrich Corp., a poly-methacrylic acid (PMA), a polyacrylic acid or polymethacrylic acid copolymer, for example a copolymer of acrylic or methacrylic acid and a further vinylmonomer, for example acrylamide, N.N-dimethyl acrylamide or N-vinylpyrrolidone, a maleic or fumaric acid copolymer, a poly(styrenesulfonic acid) (PSS), a polyamido acid, for example a carboxy-terminated polymer of a diamine and a di- or polycarboxylic acid, for example carboxy-terminated Starburst™ PAMAM dendrimers (Aldrich), a poly(2-acrylamido-2-methylpropanesulfonic acid) (poly-(AMPS)), or an alkylene polyphosphate, alkylene polyphosphonate, carbohydrate polyphosphate or carbohydrate polyphosphonate, for example a teichoic acid. Examples of anionic biopolymers or modified biopolymers are: hyaluronic acid (HA), modified HA (esterified HA or amine modified HA), glycosamino-glycanes such as heparin or chondroitin sulfate, fucoidan, poly-aspartic acid, poly-glutamic acid, carboxymethyl cellulose, carboxymethyl dextranes, alginates, pectins, gellan, carboxyalkyl chitins, carboxymethyl chitosans, sulfated polysaccharides. Preferred anionic biopolymers are alginic acid, hyaluronic acid.
- The cross-linked polymer can be formed into shape by solvent casting, hot melt extrusion or electrospinning. It is also feasible to shape the cross-linked polymer by means of compression between two heated plates as described, for instance, in WO 2007/099370. The cross-links between the nucleophilic groups of the NU-POX and the electrophilic groups of the crosslinking agent provide cohesion and the excess of electrophilic groups enables the cross-linked polymer to form links to tissue. Thus, the present invention enables the preparation of medical products that combine cohesiveness with adhesiveness.
- A very important property of POX films is that upon thorough drying to remove water they protect the interior from hydrolysis. Thus, excess (non-reacted) electrophilic groups in the crosslinked polymer will retain their activity upon storage. When a medical product containing non-reacted electrophilic groups is applied to tissue an electrophilic-nucleophilic reaction will occur between these electrophilic groups and nucleophilic reactants, notably amino or thiol groups present in tissue, thereby forming a cross linked external network (adhesion) via covalent bonding. Accordingly, the medical product advantageously is a dehydrated product containing less than 10%, even more preferably less than 5% and most preferably less than 1% water by weight of the cross-linked polymer.
- The medical product preferably contains not more than a limited amount of organic solvent. Preferably, the product contains less than 5%, more preferably less than 0.5% organic solvent by weight of the cross-linked polymer.
- For e.g. a tissue sealing tape or film, NU-POX and cross-linking agent can be mixed in any ratio needed by solvent casting or hot melt extrusion. This approach enables very precise fine tuning of the properties needed for an adhesive tissue tape or film. In case the amount of nucleophilic groups in the NU-POX is low and the number of electrophilic groups provided by the cross-linking agent is relatively high, cohesion of the resulting cross-linked polymer will be low and adhesion to tissue will be high. Naturally, it is also feasible to produce an adhesive tissue tape or film with high cohesion and high adhesion by combining a NU-POX having a high density of nucleophilic groups with an excess amount of electrophilic cross-linking agent.
- A particularly advantageous embodiment of the present medical product is an adhesive tissue tape or an adhesive tissue film. The present invention enables the preparation of a tape or film with excellent tissue-adhesive properties due to the presence of non-reacted electrophilic groups that are capable of reacting with nucleophilic groups naturally present in tissue. Furthermore, the cross-linked polymer of the present invention, due to its amorphous properties and tunable glass transition temperature, enables the preparation of cohesive, flexible and resilient tapes and films as well as tough and harder materials tailor-made for specific applications.
- The tape or film according to the present invention may be non-permeable or permeable. Non-permeable tapes or films may suitably be used to seal off tissue, e.g. to prevent infection or dehydration. Permeable tapes or films may advantageously be employed to staunch bleeding from surgical or traumatic wounds. As explained herein before it is highly advantageous if the cross-linked polymer contained in the medical product is in an amorphous state. The term “amorphous” refers to a material that is a solid and in which there is no long-range order of the positions of the molecules. This lack of order distinguishes amorphous solids from crystalline solids.
- The present invention enables the preparation of an amorphous tape or an amorphous film as the NU-POX component of the cross-linked polymer has excellent amorphous properties. These amorphous characteristics can be retained in the cross-linked polymer especially if the electrophilic cross-linking agent is a low molecular weight cross-linker as defined herein before.
- It is further preferred that the cross-linked polymer in the medical product has a glass transition temperature of at least 0° C. and most preferably at least 20° C. Typically, the glass transition temperature of the polymer does not exceed 120° C.
- The adhesive tissue tape or adhesive tissue film of the present invention offers the advantage that it can absorb substantial quantities of water to form a cohesive hydrogel. The absorption of water may result in significant swelling of the product. However, it is also possible to design the product in such a way that it does not swell significantly when it is brought into contact with moisture.
- In accordance with an advantageous embodiment, the adhesive tissue tape or adhesive tissue film as described herein before does not exhibit significant swelling when it comes into contact with moisture. Typically, these medical products have a swelling index of between 0% and not more than 100%, preferably of between 0% and not more than 30%, and most preferably of between 0% and not more than 10%. Medical products having a low swelling index can suitably be applied in repair of dural defects and spinal cord repair.
- Greater cross-linking creates a tighter network, which will decrease swelling. This can be advantageous in certain applications, for example, if the medical product is an implant, a suture material or a tissue sealant that is applied in tight locations where gel swelling can potentially cause adverse effects. In that case, the swelling index preferably does not exceed 50%, most preferably it does not exceed 10%.
- The present invention enables the preparation of an adhesive tissue tape or tissue film having excellent properties without requiring, for instance, support layers. Accordingly, the adhesive tissue tape preferably is a single layer tape. Likewise, the adhesive tissue film preferably is a single layer film.
- According to another embodiment of the invention, the medical product is a porous haemostatic product. Such a porous haemostatic product may be prepared, for instance, by converting a viscous solution of NU-POX into a foam and subsequently fixating the foam structure by cross-linking the NU-POX with the electrophilic cross-linking agent. Next, the solvent can be removed and a porous haemostatic product is obtained. Naturally, foaming agents and/or fillers can be employed in this process. Advantageously, the haemostatic product so obtained has tissue-adhesive properties due to the presence of non-reacted electrophilic groups as described herein before.
- The haemostatic product may suitably contain a carrier, preferably a water-soluble carrier. Examples of carriers that may suitably be employed include monosaccharides; di- and oligosaccharides, such as lactose, mannitol, trehalose, erythritol, xylitol, sorbitol, maltitol, isomalt, maltodextrin, cellobiose, glucose, fructose, maltulose, lactulose, maltose, gentobiose, isomaltose, lactitol, palatinitol, dulcitol, ribitol, sucrose, raffinose, gentianose, planteose, verbascose, stachyose, melezitose, inositol; and polysaccharides, such as dextran, starch (amylose, amylopectin), glycogen, cellulose, chitin, alginates, callose, chrysolaminarin, xylan, arabinoxylan, mannan, fucoidan and galactomannan; and combinations of these carbohydrates. Preferably, the carrier employed has a glass transition temperature of at least 0° C., more preferably of at least 25° C.
- Typically, the haemostatic product contains 25-75 wt. % of the NU-POX, 25-75 wt. % of the electrophilically activated cross-linking agent and 0-50 wt. % of carrier.
- In accordance with another advantageous embodiment, the present medical product is an implant. According to a particularly preferred embodiment, the cross-linked polymer contained in the implant provides a matrix to support tissue regeneration. Preferably, this is a biodegradable three-dimensional bioresorbable porous construct with attaching properties to bone material and appropriate mechanical properties to guide cellular attachment and subsequent tissue formation. For bone reconstruction, the construct is preferably also load bearing, meaning that any fluid component in the implant, or the in-situ formed implant, should be kept as low as possible. In this respect it is advantageous that only very limited amounts of plasticizers like triacetin or water are needed to render the cross-linking agent and NU-POX extrudable.
- According to an advantageous embodiment, the polymer network comprised in the present implant contains osteoconductive fillers like bone graft materials, including autologous bone, autologous bone particulate, allogenic bone graft material, human cadaver bone, xenograft bone graft material, animal bone, growth factors or synthetic materials such as hydroxyapatite, tricalcium phosphate and bioactive glass.
- The medical product of the present invention may suitably be produced in the form of fibres or a fibrous fleece. This may be achieved, for instance, by means of electrospinning or by injecting a NU-POX containing fluid into a solution containing a high concentration of the electrophilic cross-linking agent. A fibrous fleece may be produced by employing a polymeric electrophilic cross-linking agent, such as dextran aldehyde, to produce the cross-linked polymer in solution and by subsequently removing the solvent (e.g. water) by means of evaporation. Fibrous fleeces can also be produced with the help of an anionic polymeric cross-linking agent such an alginate. This may be done, for instance, by preparing a solution of NU-POX and propylene glycol alginate at low pH and by subsequently increasing the pH, thereby initiating the cross-linking reaction.
- A further aspect of the invention relates to a biocompatible, covalently cross-linked polymer that is obtained by reacting NU-POX with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate; and wherein the total number of reacted and unreacted electrophilic groups contained in the polymer exceeds the total number of reacted and unreacted nucleophilic groups contained in the polymer by at least 3%, preferably at least 5%.
- The covalently cross-linked polymer preferably is a cross-linked polymer as defined herein before.
- Another aspect of the invention relates to a kit for producing the biocompatible, cross-linked polymer, said kit comprising NU-POX and the electrophilically activated cross-linking agent as defined herein before, wherein the kit comprises separately packaged volumes of the NU-POX and the electrophilic cross-linking agent, and wherein each of the NU-POX and the electrophilic cross-linking agent is present in the form of a fluid or reconstitutable powder.
- Independently, the NU-POX and the electrophilic cross-linking agent may be provided in the form of fluid or a powder. Providing NU-POX and the cross-linking agent in the form of a fluid or reconstitutable powder allows the NU-POX and the cross-linking agent to undergo a rapid cross-linking reaction.
- Preferably, the NU-POX is provided in the form of a fluid. More specifically, it is preferred that the NU-POX is contained in a first solvent in a concentration of 1-95 wt. %, preferably of 1.5-20%, most preferably of 2-10%. The electrophilic cross-linking agent is preferably also provided in the form of a fluid. Even more preferably, the electrophilically activated cross-linking agent is contained in a second solvent in a concentration of 1-95 wt. %, preferably of 1.5-30%, preferably of 2-10%.
- In an embodiment in which both the NU-POX and the cross-linking agent are provided in the form of a fluid, said fluid may be a liquid or a viscous fluid. It is advantageous to employ both the NU-POX and the cross-linking agent in the form of a liquid of low viscosity in case both these components are to be applied, for instance, by spraying. In order to provide the NU-POX in the form of a low viscosity liquid, the NU-POX may need to be diluted substantially. In case a dilute liquid NU-POX solution is employed it is advisable to provide the cross-linking agent in a concentrated solution so as to achieve sufficient cross-linking. This may be achieved by employing a low molecular cross-linking agent as such cross-linking agents can be dissolved in high concentrations without causing high viscosities.
- In case the NU-POX and the cross-linking agent are to be applied in a way that does not require these components to be low viscosity liquids, e.g. if they are applied by means of a dual syringe with, optionally, a static mixer, both the NU-POX and the cross-linking agents may be provided in the form of viscous (gelled) fluids.
- According to another particularly preferred embodiment, the first solvent and the second solvent are selected from water, polyols, alcohols (e.g. ethanol or iso-propanol) and combinations thereof. The volume containing NU-POX and/or the volume containing the cross-linking agent advantageously contain polyol, water or a mixture of both. Furthermore, the latter volumes may suitably be buffered. The solvent(s) and buffering system employed in the present kit are suitable chosen so as to achieve an optimum cross-linking rate.
- Polyols that can suitably be employed in the present kit include glycerol, diacetin, triacetin, sorbitol and combinations thereof.
- According to a particularly preferred embodiment the first solvent and the second solvent contain 5-50 wt. % water, more preferably 10-30 wt. % water and most preferably 15-20 wt. % water.
- The separately packaged volumes of the NU-POX and the electrophilically activated cross-linking agent may suitably contain a pH modifier.
- The separately packaged volume containing the NU-POX preferably contains an alkalinizing agent that shifts the micro-environmental pH of the NU-POX containing volume to more alkaline conditions in the presence of water or bodily fluids.
- Examples of suitable alkalinizing agents include ammonia solution, ammonium carbonate, alkali metal salts including alkali metal carbonates (for instance potassium carbonate and sodium carbonate), potassium hydroxide, sodium hydroxide and sodium borate (borax), tertiary amines such as triethylamine, triethanolamine, other amines like diethanolamine and monoethanolamine, and phosphates.
- Preferably, the alkalinizing agent has a pKa at 25° C. of 8-14, in particular of 8.5-11, more particularly of 9 to 11.
- The pH of the separately packaged volume containing NU-POX preferably lies in the range of 7-12, more preferably of 8-11, most preferably of 9-10.
- The separately packaged volumes of the NU-POX and of the cross-linking agent are advantageously contained within a dispensing means from which both volumes can be dispensed simultaneously. Thus, the two agents may be delivered simultaneously and a cross-linked polymer will form in situ. By simultaneously dispensing the two reactants and delivering them at the site where they cross-linking should occur, pre-mixing can be avoided and premature cross-linking is effectively prevented. Examples of suitable dispensing means include spray dispensers, syringes, and dual syringes.
- Syringes suitably comprise a static mixer and/or a spray nozzle to ensure that the two reactants are mixed together when simultaneously expelled from said syringe.
- In accordance with a preferred embodiment at least one of the separately packaged volumes contains a visualization agent to enhance the visibility. The visualization agent (e.g. a colourant) reflects or emits light at a wavelength detectable to a human eye. Because of the inclusion of the visualization agent it is easy for users to accurately apply the reactive mixture. Examples of suitable colourants include FD&C and D&C colorants, such as FD&C Violet No. 2, FD&C Blue No. 1, D&C Green No. 6, D&C Green No. 5, D&C Violet No. 2; and natural colorants such as beetroot red, canthaxanthin, chlorophyll, eosin, saffron, carmine, indocyanine green, or colored dyes normally found in synthetic surgical sutures. Similarly, dyes such as fluoroscein and methylene blue can be used. The visualization agent may or may not become chemically bound to the hydrogel.
- In an alternative embodiment, the kit comprises a first biocompatible thin film containing the NU-POX and a second biocompatible thin film containing the electrophilically activated cross-linking agent. The two films may suitably be applied after combining the two films on top of each other. Films may suitably have been perforated to increase their specific surface area.
- The biocompatible thin film containing the NU-POX preferably comprises an alkalinizing agent as defined herein before.
- Yet another aspect of the invention concerns a kit for producing a biocompatible, cross-linked polymer, said kit comprising NU-POX and the electrophilic cross-linking agent as defined herein before, wherein the kit comprises a powder consisting of particles having a weight averaged mean diameter of 0.01-1000 μm, said particles including particles containing NU-POX and particles containing the electrophilic cross-linking agent.
- If the NU-POX or the electrophilic cross-linking agent is provided in powder form, the powder should be readily dispersible in a fluid which may be contained within the same kit.
- The particles comprised in the kit preferably have a weight averaged mean diameter of 0.5-500 μm and most preferably of 2-300 μm, said particles including particles containing NU-POX and particles containing the electrophilically activated cross-linking agent. The NU-POX and the electrophilically activated cross-linking agent may be contained in the same particles or they may be contained in different particles within the same powder.
- The aforementioned powder may suitably be used as a haemostatic powder that can be stored under ambient conditions.
- Besides the NU-POX and/or the electrophilic cross-linking agent, the particles comprised in the haemostatic powder may suitably contain a carrier, preferably a water-soluble carrier. Examples of carriers that may suitably be employed include monosaccharides; di- and oligosaccharides, such as lactose, mannitol, trehalose, erythritol, xylitol, sorbitol, maltitol, isomalt, maltodextrin, cellobiose, glucose, fructose, maltulose, lactulose, maltose, gentobiose, isomaltose, lactitol, palatinitol, dulcitol, ribitol, sucrose, raffinose, gentianose, planteose, verbascose, stachyose, melezitose, inositol; and polysaccharides, such as dextran, starch (amylose, amylopectin), glycogen, cellulose, chitin, alginates, callose, chrysolaminarin, xylan, arabinoxylan, mannan, fucoidan and galactomannan; and combinations of these carbohydrates. Preferably, the carrier employed has a glass transition temperature of at least 0° C., more preferably of at least 25° C.
- Typically, the haemostatic powder contains 25-75 wt. % of the NU-POX, 25-75 wt. % of the electrophilically activated cross-linking agent and 0-50 wt. % of carrier.
- The cross-linked polymer that can be produced with the present kits may or may not have tissue-adhesive properties. For some applications it is beneficial if the kit can be used to produce a cross-linked polymer with tissue-adhesive properties. Thus, advantageously, the cross-linking agent contained in the present kit comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the NU-POX. Thus, the NU-POX and the electrophilically activated cross-linking agent can react to form a cross-linked polymer as defined herein before.
- In-situ cross-linking characteristics of the present kits can be improved by plasticizing NU-POX with a plasticizer selected from the group of triacetin, glycerol, triethylamine and combinations thereof. Typically, the plasticizer is employed in a concentration of 1-50%, more preferably 3-15% by weight of the NU-POX.
- As explained herein before, a particularly preferred embodiment of the present kit produces a cross-linked polymer with tissue adhesive properties. This advantageous embodiment may be realized, for instance, by plasticizing NU-POX and the electrophilic cross-linking agent into a single film or tape. Before application as a tissue tape, the latter tape may be combined with another water soluble film containing an activator, or a fluid or a spreadable composition containing an activator.
- The biocompatible cross-linked polymer according to the present invention as well as the NU-POX may advantageously contain an antimicrobial agent covalently bound to one of the oxazoline unit comprised therein. More preferably, the crosslinked polymer or NU-POX contains an antimicrobial agent that is covalently bound to oxazoline units through an amide or imide group. Examples of antimicrobial agents include aminophenols, aminocresol, amino resorcinol and aminonaphtol. The antimicrobial agent may suitably be bound to the POX-polymer via a spacer group, such as an alkylene, oxyalkylane or silicone. By covalently binding an antimicrobial agent to the POX-polymer it can be ensured that the antimicrobial agent is slowly released during biodegradation of the polymer.
- The biocompatible cross-linked polymer may suitably further comprise one or more additive components selected from fillers, oxidants, crosslinkers, microgels, additional polymers, drugs and other therapeutic agents.
- The medical products according to the present invention may advantageously be used in a variety of surgical applications. Examples of these surgical applications are summarized below.
-
Neurosurgery Repair of dural defects; repair of central nervous system tissue; spinal cord repair; nerve grafting; intervertebral disc surgery and cerebrospinal fluid leaks (CSF leaks). Ophthalmic surgery Clear corneal cataract surgery; laser in situ keratomileusis (LASIK) surgery; corneal ulcer treatment; corneal transplantation; conjunctival repair; retinal attachment; punctal plugging for treatment of dry eyes; oculoplastics and blepharoplasty (eyelid lifts); vitrectomy closure and attachment of extraocular muscles. Ear, nose and throat Control of epistaxis (nosebleeds); repair of vocal cord defects; surgery tympanoplasty for repair of perforated eardrum; myringotomy (eardrum incision for drainage) with tube insertion; sinus surgery; nasal reconstructive surgery; tonsillectomy surgery and adenoidectomy surgery. Head and necksurgery Salivary gland removal; lymph node dissection and treatment of chylous leakage after neck dissection. Interventional radiology Therapeutic embolization and femoral artery closure during interventional procedures. Vascular surgery Arteriovenous fistula repair, aortic aneurysm repair and vascular anastomosis. Cardiovascular surgery Cardiac valve repair; repair of ventricular wall rupture; coronary artery anastomosis during bypass surgery; pacemaker and lead placement; aortic anastomosis and treatment of aortic dissection. Thoracic surgery Lung lobectomy; lung biopsy and pneumothorax treatment. Gastrointestinal surgery gastrointestinal anastomosis; peptic ulcer treatment; treatment of esophageal rupture; gallbladder or bile duct anastomosis; gastric bypass surgery; appendectomy; cholecystectomy (gallbladder removal); pancreatic surgery; gastrointestinal fistula repair; sealing of peritoneal dialysis catheter leakage, treatment of abdominal hernias and prevention of intra-abdominal adhesions Colorectal surgery Colonic anastomosis; rectal fistula repair; treatment of diverticular bleeding; hernia patch placement and hemorrhoidectomy. Liver surgery Liver resection and liver transplantation. Gynecologic surgery Hysterectomy; myomectomy for uterine fibroid removal; fallopian tube anastomosis; vaginal fistula repair; cervical surgery; ovarian cyst removal; breast biopsy; mastectomy and lumpectomy and management of preterm premature rupture of membranes. Urologic surgery Nephrectomy, kidney transplantation; urethral fistula repair; urethral anastomosis; repair for stress urinary incontinence; bladder closure; radical prostatectomy and vasectomy reversal surgery. Pediatric surgery Congenital cleft lip repair Orthopedic surgery Hip replacement surgery; knee replacement surgery; tendon reattachment; cartilage repair; intervertebral disc repair, fracture repair and bone grafting Plastic and Face lift surgery; closure of skin incisions; soft tissue reconstructive surgery augmentation Trauma surgery Closure of splenic lacerations and other solid organs; closure of skin lacerations; bleeding control during burn debridement and skin grafting for burn victims. - Polymeric coated gas bubbles acting as ultrasound contrast agents can suitably be embedded in the kits or the medical products described herein before. Polymeric coated gas bubbles derive their contrast properties from the large acoustic impedance mismatch between blood and the gas contained therein. Examples of polymers that can be used to coat these gas bubbles include polylactide, polyglycolide, polycaprolactone, copolymers of polylactide and polyglycolide, copolymers of lactide and lactone, polysaccharide, polyanhydride, polystyrene, polyalkylcyanoacrylate, polyamide, polyphosphazene, poly(methylmethacrylate), polyurethane, copolymers of methacrylic acid and acrylic acid, copolymers of hydroxyethylmethacrylate and methylmethacrylate, polyesters, such as polycarbonates, and protein. Preferred polymers are those which are biocompatible and/or biodegradable. In a preferred embodiment the polymer is polylactic co-glycolic acid (PLGA).
- The invention is further illustrated by means of the following non-limiting examples.
- Amphiphilic copolymers of NU-POX containing ethyl and amine groups in the alkyl side chain were synthesized by controlled acidic hydrolysis of aquazol 50 (poly(2-ethyl-2-oxazoline (PEtOx), Mw 50,000) to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer (PEtOx-PEI). 12% of the initial 2-ethyl-oxazoline units was hydrolyzed.
- This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl succinyl chloride, followed by the reaction of the methyl ester with ethylenediamine (30 equivalents in the absence of solvent) to yield an amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer.
- An amount of 1.31 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 50 ethanol (absolute), 10 μL water and 4 μL triethyl amine. A solution containing 20,000 Da N-hydroxy succinimide end capped PEG powder (DuraSeal Dural Sealant System) 8.76 mg in 50 μL water was added. The combined fluid mixture (about 115 μL with a NH2:NHS ratio of 1:1.22) turned into a cross linked network (gel) within 30 seconds at room temperature.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- An amount of 1.26 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 28 ethanol (absolute), 1.4 μL water and 0.2 μL triethyl amine. A solution containing 20,000 Da N-hydroxy succinimide end capped PEG powder (DuraSeal Dural Sealant System) 8.79 mg in 50 μL was added. The combined fluid mixture (about 80 μL with a NH2:NHS ratio of 1:1.27) was poured onto a fresh dissected bovine peritoneum. The resulting hydrogel was found to adhere to the tissue.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- An amount of 14.38 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 300 ethanol (absolute), 30 μL water and 5 μL triethyl amine and 3.69 mg of ethyl ester L-lysine diisocyanate (CAS 45172-15-4) was added. The combined fluid mixture (about 340 μL with a NH2:NCO ratio of 1:2) turned into a cross linked network (gel) within 2 minutes.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- An amount of 14.12 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 200 ethanol (absolute), 10 μL water and 1.4 μL triethyl amine and 3.69 mg of ethyl ester L-lysine diisocyanate (CAS 45172-15-4) was added. The combined fluid mixture (about 220 μL with a NH2:NCO ratio of 1:2.11) turned into a cross linked network (gel) within 20 seconds. The gel was placed onto a fresh dissected bovine peritoneum and was found to adhere to the tissue.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- An amount of 14.92 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 350 ethanol (absolute), 10 μL water and 5 μL triethyl amine and this solution was added to a solution containing 5.17 mg propylene glycol alginate (PGA) in 205 μL water. The combined fluid mixture (about 570 μL with a NH2:propylene glycol ratio of 1:1.35) turned into a cross linked network (gel) within 10 minutes.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- An amount of 14.72 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 200 ethanol (absolute), 10 μL water and 1.4 μL triethyl amine and this solution was added to a solution containing 5.59 mg propylene glycol alginate (PGA) in 205 μL water. The combined fluid mixture (about 420 μL with a NH2:propylene glycol ratio of 1:1.46) was poured onto a fresh dissected bovine peritoneum. The resulting hydrogel was found to adhere to the tissue.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- To a solution of 1 g dextran, MW 9,000-11,000 in 9 mL water, cooled to 0° C., a solution of 1 g sodium periodate in 9 mL water was added dropwise. After addition had been completed, the mixture was stirred for 4 hours at room temperature. Next, 328 mg of CaCl2 was added and stirred for 30 minutes and filtered. The resulting filtrate was combined with 350 mg potassium iodide and stirred for 30 minutes. The resulting red solution was added dropwise to 200 mL cold acetone and the agglomerated product was separated. The white solid was dissolved in water and freeze-dried, resulting in a white dextran aldehyde (MW 9,000-11,000) of which about 50% of the glucopyranose rings oxidatively cleaved to dialdehydes.
- An amount of 7.87 mg of the NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 150 μL ethanol (absolute), 15 μL water and 2.5 μL triethyl amine and this solution was added to a solution containing 12.07 mg dextran aldehyde in 150 μL water. The combined fluid mixture (about 320 μL with a NH2:aldehyde ratio of 1:8.68) turned into a cross linked network (gel) within 30 seconds.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1.
- Dextran aldehyde was synthesized as described in example 7.
- An amount of 7.28 mg of this NH2-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in a mixture of 100 ethanol (absolute), 5 μL water and 0.7 μL triethyl amine and this solution was added to a solution containing 12.72 mg dextran aldehyde in 150 μL water. The combined fluid mixture (about 260 μL with a NH2:aldehyde ratio of 1:9.89) was poured onto a fresh dissected bovine peritoneum. The resulting hydrogel was found to adhere to the tissue.
- 2-(2-Methoxycarbonylethyl)-2-oxazoline was prepared following a literature procedure (M. T. Zarka, O. Nuyken, R. Weberskirch, Chem. Eur. J. 2003, 9, 3228-3234, a modified procedure of A. Levy, M. Litt, J. Polym. Sci. A 1968, 6, 1883) followed by cationic ring-opening polymerization yielding the corresponding methylester functionalized homopolymer, poly(2-(2-methoxycarbonylethyl)-2-oxazoline).
- Homopolymerization of the 2-(2-methoxycarbonylethyl)-2-oxazoline monomer yielded poly(2-(2-methoxycarbonylethyl)-2-oxazoline) homopolymer.
- Copolymerization of the 2-(2-methoxycarbonylethyl)-2-oxazoline monomer with 2-ethyl-2-oxazoline (25, 50 and 75%) or 2-methyl-2-oxazoline (25, 50 and 75%) yielded statistical copolymers.
- The poly[2-(2-methoxycarbonylethyl)-2-oxazoline] homopolymer was reacted with N-Boc amino ethane amine by dissolving 0.8 g polymer in 2.5 mL N-Boc amino ethane amine followed by 23 hours stirring at 80° C. 1H NMR spectroscopy in CDCl3 revealed that ˜90% of the methyl ester units were converted into Boc-aminoethyl amido side chains. This polymer was further reacted with hydrochloric acid (HCl) by dissolving 850 mg of polymer in dichloromethane (30 mL), which was added dropwise to a HCl solution in ethyl acetate (0.175 mL, 2.98 mmol). After complete addition, the solution was stirred for 6 hours at room temperature. 1H NMR spectroscopy demonstrated the successful formation of the hydrochloric acid salt of amino-ethyl amido side chain functionalized polymer by disappearance of the Boc signal at 1.4 ppm to yield >90% amine-side chain activated poly[2-(amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- The copolymer of 2-ethyl-2-oxazoline containing 25% 2-methoxycarbonyl ethyl-2-oxazoline was functionalized by the reaction of the methyl ester side chains with ethylenediamine (30 equivalents in the absence of solvent) to yield exactly 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- The copolymer of 2-methyl-2-oxazoline containing 25% 2-methoxycarbonyl ethyl-2-oxazoline was functionalized by the reaction of the methyl ester side chains with ethylenediamine (30 equivalents in the absence of solvent) to yield exactly 25% amine-side chain activated poly[2-(methyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX).
- The poly[2-(2-methoxycarbonylethyl)-2-oxazoline] homopolymer was functionalized in two-step approach by partial hydrolysis (25, 50 and 75%) with LiOH of the methylester to the carboxylic acid, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly(NHS-ester-ethyl-oxazoline/methoxycarbonylethyl oxazoline) copolymer (EL-POX). The final functionalization degree with NHS was confirmed by UV-Vis spectroscopy and 1H NMR spectroscopy to be very close to 25, 50 and 75%.
- Copolymers of 2-ethyl-2-oxazoline containing 25, 50 or 75% methylester units and copolymers of 2-methyl-2-oxazoline containing 25, 50 or 75% methylester units were functionalized in two-step approach by quantitative hydrolysis with LiOH of the methylester to the carboxylic acid, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline]polymer (EL-POX). The final functionalization with NHS was confirmed by UV-Vis spectroscopy and 1H NMR spectroscopy to be exactly 25, 50 and 75%.
- Polymers of EL-POX containing NHS groups in the alkyl side chain were synthesized by >95% acidic hydrolysis of Aquazol-50 (poly(2-ethyl-2-oxazoline, PEtOx, Mn 50,000) to yield linear poly(ethylene imine) (LPEI). LPEI was functionalized in a two-step approach by coupling of succinic anhydride in DMSO, followed by activation of the obtained carboxylic acid moieties with NHS in the presence of diisopropyl carbodiimide and triethylamine to synthesize NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer. The final functionalization with NHS was confirmed by UV-Vis spectroscopy and 1H NMR to be >95% (EL-POX). This compound was water insoluble.
- LPEI was functionalized in an identical two-step approach with 25, 50 and 75% stoichiometric amounts of NHS, with reference to the carboxylic acid moieties, in the presence of diisopropyl carbodiimide and triethylamine to synthesize resp. 25, 50 and 75% NHS-side chain activated poly(NHS-ester-ethyl-oxazoline/carboxyethyl oxazoline) copolymers. The final functionalization degree with NHS was confirmed by UV-Vis spectroscopy and 1H NMR spectroscopy to be approximately 25, 50 and 75%. These EL-POX compounds were water soluble and soluble in 10/90 v/v % water/methanol, resp. water/ethanol mixtures.
- An amount of 1.16 mg of the 25% amine-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer described in Example 9 was dissolved in a mixture of 10 μL ethanol:triethyl amine (99:1) and this solution was added to a solution containing 8.84 mg of the 25% NHS-side chain activated poly[2-(2-methoxycarbonylethyl)/(2-ethyl-NHS esters)-2-oxazoline] copolymer in 70 μL ethanol. The combined fluid mixture (about 90 μL with a NHS:NH2 ratio of 5:1) turned into a cross linked network (gel) within 60 seconds.
- This example illustrates that NU-POX can suitably be cross-linked with a NHS-functional polymer.
- Amine-side chain activated poly[2-(ethyl/NHS-ester-ethyl)]-2-oxazoline copolymer (NU-POX) was synthesized by controlled acidic hydrolysis of aquazol 50 (poly(2-ethyl-2-oxazoline (PEtOx), Mw 50,000) to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer (PEtOx-PEI) in which 12% of the initial 2-ethyl-oxazoline units was hydrolyzed.
- This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl succinyl chloride in the presence of triethylamine, followed by the reaction of the formed methyl ester side chain with ethylenediamine to yield an amine-side chain activated poly(2-ethyl/amino-ethyl-amide-ethyl)-2-oxazoline copolymer.
- This NU-POX was turned into an EL-POX by reacting the amine with maleic anhydride to yield maleimide-side chain activated poly(2-ethyl/maleimide-ethyl-amide-ethyl)-2-oxazoline copolymer.
- POX containing >95% NHS moieties in the alkyl side chain was synthesized as described in Example A. This EL-POX was reacted with cysteamine hydrochloride to synthesize the thiol containing polymer which was crosslinked by disulfide bonds. The identity was confirmed by 1H NMR (NU-POX).
- The disulfide bonds were reduced with tris(2-carboxyethyl)phosphine (TCEP). Crosslinking of the thiol side chain activated polymer (10 mg in 500 μL) was tested with maleimide-side chain activated poly(2-ethyl/maleimide-ethyl-amide-ethyl)-2-oxazoline copolymer (6 mg in 100 μL) in the presence of 100 μL triethylamine (TEA).
- Crosslinking in 600 μL DMSO/MeOH (2:5 v/v) in the presence of TEA (100 μL) was confirmed using 6 mg EL-POX and 5 mg NU-POX from this example. A gel was formed within 20 seconds at room temperature.
- Polymers containing 2-thiazoline-2-thioesters in the alkyl side chain were synthesized by the following procedure.
- POX containing >95% carboxylic acid moieties in the alkyl side chain was synthesized as described in Example A. This POX was activated with 2-thiazoline-2-thiol in the presence of diisopropyl carbodiimide and triethylamine to synthesize 2-thiazoline-2-thioester-side chain activated poly[2-(thiazoline-thioester-ethyl)-2-oxazoline]polymers (EL-POX). The identity of this EL-POX was confirmed by 1H NMR.
- Amphiphilic copolymers of NU-POX containing ethyl and NH2 groups in the alkyl side chain were synthesized as described in example 1:12% of the initial 2-ethyl-oxazoline units were hydrolyzed.
- Crosslinking in 400 μL DMSO/MeOH (1:1 v/v) without addition of base was confirmed using 7.0 mg EL-POX and 15.8 mg NU-POX from this example. A gel was formed within 30 seconds at room temperature.
- This example illustrates that NU-POX can suitably be cross-linked with a thiazoline-functional polymer.
- Polymers containing aldehyde functionalities in the alkyl side chain were synthesized by the following procedure.
- EL-POX containing >95% N-hydroxysuccinimide (NHS) groups in the alkyl side chain was synthesized as described in Example A. This EL-POX was reacted with 2-(1,3-Dioxolan-2-yl)ethanamine to synthesize a polymer containing >95% protected aldehyde functionality. The polymer was deprotected using a previously described procedure (Taubmann, C., Luxenhofer, R., Cesana, S. and Jordan, R. (2005), First Aldehyde-Functionalized Poly(2-oxazoline)s for Chemoselective Ligation. Macromol. Biosci., 5: 603-612.) which yielded the >95% aldehyde functionalized polymer (EL-POX). The identity was confirmed by 1H-NMR and 13C-NMR.
- Crosslinking in 400 μL DCM/MeOH (1:1, v/v) without addition of base was confirmed using 7.0 mg EL-POX from this example and 15.8 mg NU-POX from example 1. A gel was formed within 60 seconds at room temperature.
- This example illustrates that NU-POX can suitably be cross-linked with an aldehyde-functional polymer.
- NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline] copolymer, containing 50% NHS units and 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer were prepared as described in Example A.
- The NHS-side chain activated poly[2-(NHS-ester-ethyl)-2-oxazoline] copolymer, containing 50% NHS units was dissolved in ethanol (absolute). Separately, the 25% amine-side chain activated poly[2-(ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was dissolved in ethanol (absolute). To both solutions a small amount of glycerol (plasticizer) had been added. The solutions were mixed for solvent casting and the mixture was dried to an amorphous tape by means of vacuum at room temperature.
- The burst pressure of this formulation was tested in the following manner. Collagen casing of consistent properties and thickness (sausage casing, Nippi Casing Co. (#320),4) was used (substrate). Sections of the substrate were washed in deionized water to remove glycerine and soaked in fresh deionized water for five minutes. A 3 mm circular incision was cut into the substrate, which was then secured to a burette in such a manner that simulated body fluid could be forced out under measurable pressure via the circular incision.
- The amorphous tape was put onto the secured substrate to form a seal. After a few minutes, the pressure of the simulated body fluid was increased to the point that the seal burst (burst pressure). The burst pressure was found to be adequate for a sealing tape. The NHS:amine ratio in this film was 5:1.
- A syringe comprising two separate reservoirs and a static mixing unit to mix the contents of the reservoirs when the two reservoirs are emptied simultaneously was filled with two viscous fluids.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer (NU-POX) was synthesized as described in example 1 and 75% NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer (EL-POX) was prepared as described in example A.
- The NU-POX was weighed accurately into a vessel containing water and the contents (50/50 w/w) were mixed well. The first reservoir of the syringe was filled with the NU-POX gel taking care to exclude large air bubbles. The second reservoir of the syringe was filled with an aqueous EL-POX solution that had been prepared in an identical manner. The amine-NHS ratio was 1:5.
- Both the static mixer and plunger were attached and the two gels were extruded through the static mixture to form a homogenous, clear, cross linked polymeric phase with an initial setting time of less than 1 minute.
- The dual syringe experiment as described in example F was repeated. In this experiment however, the EL-POX was dissolved in glycerol 85% and the final amine-NHS ratio was 1:1.
- Both the static mixer and plunger were attached and the two gels were extruded through the static mixture to form a homogenous, clear, cross linked polymeric phase with an initial setting time of less than 1 minute.
- NH2-side chain activated poly[(2-ethyl/amine-ethyl-amide-ethyl)-2-oxazoline] copolymer was synthesized as described in example 1 (NU-POX) and 75% NHS-side chain activated poly(NHS-ester-ethyl-oxazoline) polymer was synthesized as described in example A (EL-POX). N-hydroxy succinimide end capped PEG powder 20,000 Da [PEG-NHS] was obtained form a DuraSeal, Dural Sealant System and trilysine was purchased from Sigma. The number of electrophilic groups/molecule of EL-POX was approximately 375 and the number of electrophilic groups/molecule of PEG-NHS was approximately 4. The number of nucleophilic groups/molecule of NU-POX was approximately 29 and the number of electrophilic groups/molecule of trilysine was 4.
- Separately, the NU-POX and the PEG-NHS were dissolved in water containing the same amount (w/w) of trehalose, snap freezed with the aid of liquid nitrogen and freeze dried overnight yielding respectively, NU-POXt and PEG-NHSt.
- The EL-POX was dissolved in water containing the same amount (w/w) of trehalose including citrate buffer (pH 5.5 after reconstitution in water), snap freezed with the aid of liquid nitrogen en freeze dried overnight yielding EL-POXt. Trilysine was dissolved in water containing a 100 fold amount (w/w) of trehalose, snap freezed with the aid of liquid nitrogen en freeze dried overnight yielding trylisine-t.
- 1.0 mL of heparinized fresh, whole blood was added to the freeze dried formulations, and combinations thereof at room temperature and mixed to assess haemostatic properties (using the tube inversion test). The results of these experiments are depicted in Table 1. A carbonate-bicarbonate buffer (1 mg Na2CO3+13 mg NaHCO3) was added in dry salt form to the freeze dried formulations prior to addition of the blood. Addition of the blood to the formulations with the carbonate/bicarbonate buffer resulted in a final pH of 9.
-
TABLE 1 Time to EL-POXt PEG-NHSt NU-POXt Trilysine-t haemostasis Exp. (mg) (mg) (mg) (mg) (min) A 49 1.5 B 52 9 1.0 C 49 30 >3 - From these results it is clear that formulations A and B exhibited adequate haemostatic properties. Best results were obtained for the formulation containing a combination of NU-POX and EL-POX, indicating that the cross-linking imparted improved haemostatic properties. Furthermore, it was found that the cross-linking yielded a stronger gel. Without buffer, experiment B lead to a gel in about 15 minutes.
- Experiment C did not lead to any gelation and/or haemostasis.
Claims (24)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12159982.3 | 2012-03-16 | ||
EP12159982 | 2012-03-16 | ||
EP12159982 | 2012-03-16 | ||
PCT/NL2013/050187 WO2013137736A1 (en) | 2012-03-16 | 2013-03-15 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2013/050187 A-371-Of-International WO2013137736A1 (en) | 2012-03-16 | 2013-03-15 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/210,606 Continuation US9868822B2 (en) | 2012-03-16 | 2016-07-14 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150045507A1 true US20150045507A1 (en) | 2015-02-12 |
US9416228B2 US9416228B2 (en) | 2016-08-16 |
Family
ID=47997739
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/385,119 Active US9416228B2 (en) | 2012-03-16 | 2013-03-15 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
US15/210,606 Active US9868822B2 (en) | 2012-03-16 | 2016-07-14 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/210,606 Active US9868822B2 (en) | 2012-03-16 | 2016-07-14 | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline |
Country Status (8)
Country | Link |
---|---|
US (2) | US9416228B2 (en) |
EP (1) | EP2825582B1 (en) |
JP (2) | JP6178399B2 (en) |
CN (1) | CN104271638B (en) |
BR (1) | BR112014022821B1 (en) |
ES (1) | ES2563246T3 (en) |
HK (1) | HK1206049A1 (en) |
WO (1) | WO2013137736A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180087759A (en) * | 2017-01-25 | 2018-08-02 | 국방과학연구소 | Fiber comprising substituted poly[2-(3-butenyl)-2-oxazoline] and nylon-6,6 and method for producing the same |
US10549015B2 (en) * | 2014-09-24 | 2020-02-04 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
CN114126672A (en) * | 2019-07-12 | 2022-03-01 | 加特技术公司 | Hemostatic powder |
CN114206988A (en) * | 2019-07-30 | 2022-03-18 | 加特技术公司 | Polyoxazoline copolymers comprising calcium binding groups |
US11571492B2 (en) * | 2017-08-04 | 2023-02-07 | Hcs Innovation, Llc | Natural polymer-based tissue adhesive with healing-promoting properties |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201909167T4 (en) * | 2011-01-04 | 2019-07-22 | Gatt Tech B V | Cross-linked polymers and implants derived from electrophilically activated polyoxazoline. |
CN104271638B (en) * | 2012-03-16 | 2016-11-02 | 本德尔分析控股公司 | Come from cross-linked polymer and the medical products of nucleophilic reactivity polyoxazoline |
DE102013016750A1 (en) | 2013-10-02 | 2015-04-02 | Friedrich-Schiller-Universität Jena | New poly (ethyleneimine) based copolymers for attachment and release of genetic material, in particular DNA / RNA, as well as methods for their preparation and use |
CN107106719B (en) * | 2014-10-06 | 2021-06-01 | 加特技术公司 | Tissue-adhesive porous hemostatic product |
EP3344299B1 (en) * | 2015-09-01 | 2021-08-11 | Baxter International Inc | Hemostatic material |
CN113372579B (en) * | 2015-09-09 | 2023-07-14 | 苏黎世联邦理工学院 | Injectable macroporous hydrogels |
KR102489614B1 (en) * | 2016-05-27 | 2023-01-16 | 삼성전자주식회사 | Oxazoline modified copolymer, composition including oxazoline modified copolymer, and article manufactured from the composition |
CN106075549B (en) * | 2016-06-17 | 2020-02-14 | 广州迈普再生医学科技股份有限公司 | Tissue sealing glue composition, tissue sealing glue and preparation method and application thereof |
WO2019053269A1 (en) * | 2017-09-15 | 2019-03-21 | Université De Strasbourg | Injectable hybrid alginate hydrogels and uses thereof |
CN109694484B (en) * | 2017-10-20 | 2021-08-27 | 四川大学华西医院 | Immunologic adjuvant and preparation method thereof |
CN108939174B (en) * | 2018-07-16 | 2020-06-19 | 浙江大学 | Layer-by-layer self-assembled multilayer film of pH response type polyoxazoline-nano silver and preparation method thereof |
CN109182260A (en) * | 2018-09-11 | 2019-01-11 | 邵勇 | A kind of method of in vitro culture fetal membrane mescenchymal stem cell |
CN109776808B (en) * | 2019-02-01 | 2020-06-30 | 浙江大学 | Preparation method of water-soluble modified chitosan |
CN109731133B (en) * | 2019-02-01 | 2020-09-01 | 浙江大学 | Antibacterial, anti-adhesion and injectable temperature-sensitive chitosan gel dressing and preparation method thereof |
EP3996757B1 (en) * | 2019-07-12 | 2023-04-19 | GATT Technologies B.V. | Biocompatible, flexible, haemostatic sheet |
CA3146724A1 (en) * | 2019-07-12 | 2021-01-21 | Gatt Technologies B.V. | Biocompatible, flexible, haemostatic sheet |
EP3958907A1 (en) * | 2019-08-28 | 2022-03-02 | Boston Scientific Scimed Inc. | Multi-armed polyoxazolines and compositions, systems and methods pertaining to the same |
WO2021143736A1 (en) * | 2020-01-16 | 2021-07-22 | The Hong Kong University Of Science And Technology | Compositions and methods for controlled release of target agent |
CN111803454B (en) * | 2020-07-01 | 2022-05-06 | 中国科学院长春应用化学研究所 | Support material, preparation method and application thereof |
US20230310698A1 (en) * | 2020-07-28 | 2023-10-05 | Gatt Technologies B.V. | Bone-adhesive sheet |
WO2022148725A1 (en) * | 2021-01-08 | 2022-07-14 | Gatt Technologies B.V. | Bioresorbable sealing powder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042473A1 (en) * | 1995-12-18 | 2002-04-11 | Trollsas Olof Mikael | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US20120041481A1 (en) * | 2004-04-28 | 2012-02-16 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB760311A (en) | 1951-10-06 | 1956-10-31 | Allied Colloids Mfg Company Lt | Improvements in and relating to derivatives of ethylene imine |
US3442975A (en) | 1967-01-11 | 1969-05-06 | Allied Chem | Polyimine/polycarbonamide graft polymers |
US3996237A (en) | 1974-07-17 | 1976-12-07 | The Dow Chemical Company | Oxazoline- or oxazine-substituted acrylic esters |
US5635571A (en) | 1995-06-30 | 1997-06-03 | Cornell Research Foundation, Inc. | Polymerizable macromonomers and polymers prepared therefrom |
US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
US6566406B1 (en) | 1998-12-04 | 2003-05-20 | Incept, Llc | Biocompatible crosslinked polymers |
US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
EP1183298A1 (en) | 1999-05-19 | 2002-03-06 | Basf Aktiengesellschaft | Cross-linked polymers that contain condensed alkaline amino acids and method for producing said polymers |
DE10152407A1 (en) | 2001-10-24 | 2003-05-08 | Aesculap Ag & Co Kg | Composition of at least two biocompatible chemically crosslinkable components |
US7300738B2 (en) | 2003-02-10 | 2007-11-27 | Fujifilm Corporation | Azolinyl acetic acid derivative and azolinyl acetic acid derivative containing recording material |
JP2005161698A (en) | 2003-12-03 | 2005-06-23 | Fuji Photo Film Co Ltd | Recording material |
US20050238825A1 (en) | 2004-04-26 | 2005-10-27 | Isp Investments Inc. | Crosslinked polymeric composition |
WO2006034128A2 (en) | 2004-09-17 | 2006-03-30 | Angiotech Biomaterials Corporation | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
WO2007099370A2 (en) | 2006-03-01 | 2007-09-07 | Tissuemed Limited | Tissue-adhesive formulations |
US7943141B2 (en) * | 2007-02-28 | 2011-05-17 | Serina Therapeutics, Inc. | Activated polyoxazolines and compositions comprising the same |
US8067028B2 (en) * | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
WO2009043027A2 (en) * | 2007-09-27 | 2009-04-02 | Serina Therapeutics, Inc. | Multi-armed forms of activated polyoxazoline and methods of synthesis thereof |
US8110651B2 (en) | 2008-01-11 | 2012-02-07 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
FR2928373B1 (en) | 2008-03-05 | 2010-12-31 | Centre Nat Rech Scient | LINEAR POLYETHYLENIMINE DERIVATIVE POLYMER FOR GENE TRANSFER. |
KR101647334B1 (en) | 2008-07-10 | 2016-08-10 | 세리나 쎄라퓨틱스, 인코포레이티드 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
US20110166063A1 (en) | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
EP2522376B1 (en) | 2008-10-17 | 2020-01-08 | Sofradim Production | Method for preparing auto-sealant matrix for tissue repair |
CN105833337B (en) | 2008-11-19 | 2020-01-21 | 阿克塔马克斯手术器材有限责任公司 | Fibrous tissue sealant and method of use |
TR201909167T4 (en) * | 2011-01-04 | 2019-07-22 | Gatt Tech B V | Cross-linked polymers and implants derived from electrophilically activated polyoxazoline. |
CN104271638B (en) * | 2012-03-16 | 2016-11-02 | 本德尔分析控股公司 | Come from cross-linked polymer and the medical products of nucleophilic reactivity polyoxazoline |
-
2013
- 2013-03-15 CN CN201380022653.3A patent/CN104271638B/en active Active
- 2013-03-15 EP EP13712382.4A patent/EP2825582B1/en active Active
- 2013-03-15 WO PCT/NL2013/050187 patent/WO2013137736A1/en active Application Filing
- 2013-03-15 US US14/385,119 patent/US9416228B2/en active Active
- 2013-03-15 BR BR112014022821-3A patent/BR112014022821B1/en active IP Right Grant
- 2013-03-15 JP JP2015500378A patent/JP6178399B2/en active Active
- 2013-03-15 ES ES13712382.4T patent/ES2563246T3/en active Active
-
2015
- 2015-07-15 HK HK15106748.5A patent/HK1206049A1/en unknown
-
2016
- 2016-07-14 US US15/210,606 patent/US9868822B2/en active Active
-
2017
- 2017-07-13 JP JP2017137167A patent/JP6372000B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042473A1 (en) * | 1995-12-18 | 2002-04-11 | Trollsas Olof Mikael | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US20120041481A1 (en) * | 2004-04-28 | 2012-02-16 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
Non-Patent Citations (1)
Title |
---|
Cesana, S., et al.; Macromolecular Chemistry and Physics, 2006, p. 183-192 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10549015B2 (en) * | 2014-09-24 | 2020-02-04 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
KR20180087759A (en) * | 2017-01-25 | 2018-08-02 | 국방과학연구소 | Fiber comprising substituted poly[2-(3-butenyl)-2-oxazoline] and nylon-6,6 and method for producing the same |
KR101892955B1 (en) | 2017-01-25 | 2018-08-29 | 국방과학연구소 | Fiber comprising substituted poly[2-(3-butenyl)-2-oxazoline] and nylon-6,6 and method for producing the same |
US11571492B2 (en) * | 2017-08-04 | 2023-02-07 | Hcs Innovation, Llc | Natural polymer-based tissue adhesive with healing-promoting properties |
CN114126672A (en) * | 2019-07-12 | 2022-03-01 | 加特技术公司 | Hemostatic powder |
CN114206988A (en) * | 2019-07-30 | 2022-03-18 | 加特技术公司 | Polyoxazoline copolymers comprising calcium binding groups |
Also Published As
Publication number | Publication date |
---|---|
JP2015511507A (en) | 2015-04-20 |
JP6178399B2 (en) | 2017-08-09 |
ES2563246T3 (en) | 2016-03-11 |
CN104271638A (en) | 2015-01-07 |
BR112014022821A2 (en) | 2017-06-20 |
US9868822B2 (en) | 2018-01-16 |
BR112014022821A8 (en) | 2018-07-31 |
BR112014022821B1 (en) | 2021-03-30 |
US9416228B2 (en) | 2016-08-16 |
CN104271638B (en) | 2016-11-02 |
EP2825582B1 (en) | 2016-01-13 |
JP2017221679A (en) | 2017-12-21 |
EP2825582A1 (en) | 2015-01-21 |
HK1206049A1 (en) | 2015-12-31 |
WO2013137736A1 (en) | 2013-09-19 |
US20160319075A1 (en) | 2016-11-03 |
JP6372000B2 (en) | 2018-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9868822B2 (en) | Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline | |
US10925996B2 (en) | Cross-linked polymers and implants derived from electrophilically activated polyoxazoline | |
Bouten et al. | The chemistry of tissue adhesive materials | |
US8003705B2 (en) | Biocompatible hydrogels made with small molecule precursors | |
ES2398675T3 (en) | Derived tertiary amines and their use | |
GB2561947A (en) | Tissue-adhesive materials | |
LINE | Tissue adhesives have many potential medical applications, including wound closure, supplementing or replacing sutures or staples in surgical procedures, adhesion of synthetic onlays or inlays to the cornea, drug delivery devices, and as anti-adhesion barriers to prevent post-surgical adhesions. Conventional tissue adhesives include fibrin sealants, cyanoacrylate based |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BENDER ANALYTICAL HOLDING B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENDER, JOHANNES CASPAR MATHIAS ELIZABETH;HOOGENBOOM, RICHARD;VAN HEST, JAN CORNELIS MARIA;AND OTHERS;SIGNING DATES FROM 20140807 TO 20140910;REEL/FRAME:034092/0201 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: GATT TECHNOLOGIES BV, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENDER ANALYTICAL HOLDING B.V.;REEL/FRAME:044157/0830 Effective date: 20171013 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |